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Ex vivo drug testing is a promising approach to identify novel treatment 
strategies for acute myeloid leukemia. However, accurate blast-specific drug 
responses cannot be measured with homogeneous “add-mix-measure” cell 
viability assays. In this study, we implemented a flow cytometry-based 
approach to simultaneously evaluate the ex vivo sensitivity of different cell 
populations in 34 primary acute myeloid leukemia samples to seven drugs 
and 27 rational drug combinations. Our data demonstrate that different cell 
populations present in acute myeloid leukemia samples have distinct 
sensitivity to targeted therapies. Particularly, blast cells of FAB M0/1 acute 
myeloid leukemia showed high sensitivity to venetoclax. In contrast, 
differentiated monocytic cells abundantly present in M4/5 subtypes showed 
resistance to Bcl-2 inhibition, whereas immature blasts in the same samples 
were sensitive, highlighting the importance of blast-specific readouts. 
Accordingly, in the total mononuclear cell fraction the highest BCL2/MCL1 
gene expression ratio was observed in M0/1 and the lowest in M4/5 acute 
myeloid leukemia. Of the seven tested drugs, venetoclax had the highest 
blast-specific toxicity, and combining venetoclax with either MEK inhibitor 
trametinib or JAK inhibitor ruxolitinib effectively targeted all venetoclax-
resistant blasts. In conclusion, we show that ex vivo efficacy of targeted 
agents and particularly Bcl-2 inhibitor venetoclax is influenced by the cell type, 




The treatment of acute myeloid leukemia (AML) with high-dose cytarabine 
and anthracycline-based intensive chemotherapy has remained the standard 
of care for the last four decades.1 Despite the increase in overall survival, only 
35 to 40% of adult patients under 60 years are cured with chemotherapy and 
allogeneic stem cell transplantation.2 A number of novel targeted agents have 
been investigated in AML, but have usually generated clinical responses only 
in small patient subsets. Currently, genetic profiling is used for patient 
stratification and determination of treatment, evident by the recent approvals 
of midostaurin/gilteritinib and ivosidenib/enasidenib for treating AML patients 
with FLT3 or IDH1/IDH2 mutations, respectively.3–5 Furthermore, Bcl-2 
inhibitor venetoclax combined with a hypomethylating agent was recently 
approved for AML with increased efficacy in patients with IDH1/2 and NPM1 
mutations.6,7 However, the majority of AML patients lack actionable mutations 
and our understanding of the relationship between cancer genotype, 
phenotype and drug function remain limited. Ex vivo drug testing with primary 
patient samples may help to identify novel treatment options and patient 
subgroups with sensitivity to a specific targeted therapy. 
 
AML is diagnosed when the bone marrow (BM) contains at least 20% of 
myeloid lineage blast cells, and hematological relapse is defined when the BM 
exceeds 5% of blasts. The non-blast cells of the AML BM are comprised of 
other cell types, mainly lymphocytes and more mature leukemic cells 
(monocytes, granulocytes) or healthy cells. The BM content and the maturity 
level of leukemic cells is reflected in the French-American-British (FAB) 
subtypes.8 In FAB M0/1 subtypes, the differentiation blockade occurs at the 
early myeloid progenitor stage, whereas in FAB M4/5 subtypes the 
differentiation blockade is “leaky”. In addition to immature blasts in FAB M4/5 
samples, leukemic cells often show myelomonocytic or monocytic 
differentiation, respectively. To achieve optimal response in patients, the 
drugs should target the less differentiated leukemic blasts.9 However, due to 
cellular heterogeneity, blast-specific drug responses are challenging to 
measure with conventional cell viability assays such as CellTiter-Glo (CTG) or 
tetrazolium reduction assays (MTT/MTS).10 Although enrichment of blasts is 
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possible, this can be time consuming and enrichment might deplete cell 
populations such as monocytes that secrete cytokines important for blast cell 
survival and drug responses.11–13 
 
To evaluate the ex vivo sensitivity of AML patient samples at a cell population 
level, we applied a multiplexed, 96-well format flow cytometry (FC)-based 
drug sensitivity assay. We compared this approach with the CTG-based cell 
viability assay to study potential inconsistencies between these two methods. 
Furthermore, we aimed to identify drugs and drug combinations that could 
effectively target leukemic blasts in physiologically relevant concentrations. In 
addition to standard of care drugs, cytarabine and idarubicin, we selected five 
FDA-approved targeted small molecule inhibitors that have shown AML-
selective responses in our earlier studies:14,15 MEK inhibitor (trametinib), 
JAK1/2 inhibitor (ruxolitinib), mTORC1 inhibitor (everolimus), FLT3/broad 
range tyrosine kinase inhibitor (TKI, sunitinib) and Bcl-2 inhibitor (venetoclax). 
Most importantly, we demonstrate that targeted agents, particularly 




Methods are described in more detail in the Online Supplemental Material.  
Patient samples 
BM samples from 34 AML patients and three healthy volunteers were 
obtained from Helsinki University Hospital Comprehensive Cancer Center 
after informed consent (permit numbers 239/13/03/00/2010, 
303/13/03/01/2011, Helsinki University Hospital Ethics Committee) and in 
compliance with the Declaration of Helsinki. Patient characteristics are 
presented in Supplemental Table 1.  
 
Preparation of drug plates 
The compounds (Supplemental Table 2) were dispensed on 96-well V-bottom 
plates (Thermo Fisher Scientific, Carlsbad, CA) and 384-well plates (Corning, 
Corning, NY) using an acoustic liquid handling device Echo 550 (Labcyte, 
Sunnyvale, CA). Drug plate layouts and concentrations are presented in 
Supplemental Figure 1. BM mononuclear cells (BM-MNCs) were isolated 
using Ficoll-Paque Premium (GE Healthcare, Little Chalfont, Buckinhamshire, 
UK) density gradient centrifugation. Fresh or frozen BM-MNCs were 
suspended in mononuclear cell medium (MCM; PromoCell, Heidelberg, 
Germany) supplemented with 10 μg/mL gentamicin and 2.5 μg/mL 
amphotericin B and plated in parallel on pre-drugged 96-well plates (100,000 
cells/well in 100 μl) for FC analysis and 384-well plates (10,000 cells/well in 
25 μl) for CellTiter-Glo® (CTG)-based cell viability assay. The cells were 
incubated with the drugs for 72 hours at 37°C and 5% CO2.  
 
Flow cytometry-based readouts 
Following the 72-hour incubation with the drugs, cells were stained with an 
antibody mix (CD33, CD45, CD14, CD38 and CD34) followed by apoptosis 
(Annexin-V) and dead (7-AAD) cell staining. A detailed description of the 
methods is presented in Online Supplemental Material and the gating strategy 
is illustrated in Figure 1B. 
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Cell viability analysis using CellTiter-Glo® 
Parallel to FC analysis, cell viability was measured with CellTiter-Glo® (CTG; 
Promega, Madison, WI) in 384-well plates as described earlier.14 After the 72-
hour incubation with the drugs, 25 μL CTG was added to each well. The 
luminescence signal was measured using a PHERAstar plate reader (BMG 
LABTECH, Ortenberg, Germany). 
 
Calculation of the drug sensitivity and drug combination scores 
Ex vivo drug sensitivity of AML and healthy BM cells to the tested drugs was 
calculated using a drug sensitivity score (DSS) as previously described.16 
Drug combination efficacies were calculated as the difference between 
observed and expected values. The expected value is computed using the 
Bliss independence model17 as reference, which assumes that two drugs 
exhibit their effect independently.18 
 
Gene expression and pathway analysis 
Publicly available microarray data from the Hemap data set19,20 
(http://hemap.uta.fi/) and RNA-seq data (RSEM values) from the TCGA 
Research Network21 (http://cancergenome.nih.gov/) also included in the 
Hemap resource were used for gene expression and pathway analysis. Beat 
AML data22 was used to assess the correlation between venetoclax drug 
sensitivity and BCL2 family and monocytic/granulocytic differentiation marker 
gene expression. For analysis of gene expression in healthy hematopoietic 
cell types Differentiation Map data was used.23 Detailed methods are 
described in the Online Supplemental Material. 
 
Statistical analysis 
Statistical analysis was conducted with Graph Prism version 7.0 (GraphPad 
Software, San Diego, CA). Differences between drug responses were 
analyzed by Mann-Whitney U test, and for multiple t-tests p-values were 
adjusted using the Benjamin-Hochberg method (q<0.10 used to determine 
significance). The Kruskal-Wallis test was used when more than two groups 
were tested and significant comparisons were validated with post-hoc analysis 
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(Dunn’s test). Statistical dependence between two variables was assessed by 
Spearman’s rank correlation. 
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RESULTS 
Analysis of the AML bone marrow compartment 
To measure blast-specific drug responses in mononuclear cell (MNC) 
enriched BM AML samples, we tested 34 AML samples collected at diagnosis 
or relapse with seven drugs. Following a 72-hour drug treatment we analyzed 
the samples by both FC and CTG-based cell viability assays (Figure 1A). With 
the CTG assay we measured the overall BM-MNC sensitivity, while with the 
FC analysis we measured the number of viable cells in different cell 
populations. We used four cell surface markers (CD45, CD34, CD33, CD14) 
to identify the major leukocyte populations present in the AML BM: leukemic 
blasts, immature granulocytes, promonocytes/monocytes and lymphocytes 
(Figure 1B). In the studied samples, the fraction of blasts out of CD45+ 
positive leukocytes varied between 17-92% and the lymphocyte population 
ranged from 1 to 49% (Supplemental Table 3). As expected, we observed 
high numbers of monocytic cells in FAB M4/5 samples, whereas M0/1 
samples mainly consisted of blasts and lymphocytes (Figure 1C). After 72-
hours in culture, we observed monocytic maturation in several M5 samples,24 
and in many samples the granulopoietic cell population diminished or was 
completely lost (Supplemental Figure 2).  
 
Flow cytometry vs. homogeneous cell viability assay-based drug 
sensitivity profiling  
To determine the correlation between drug sensitivity of the samples 
measured by FC or CTG-based methods, we converted the cell viability 
readouts from each assay to drug sensitivity scores (DSS, a drug sensitivity 
metric based on area under the dose-response curve, higher DSS indicates 
higher sensitivity).16 We observed a strong correlation between CTG and FC 
viability derived DSS when all live CD45+ leukocytes were used as the FC 
readout (R=0.64, P<0.0001, Figure 2A), and when the blast-specific drug 
responses were exclusively taken as the FC readout from samples with blast 
counts over 50% (R=0.75, P<0.0001, Figure 2B). However, we observed poor 
correlation between the FC and CTG results in a sample cohort with blast 
counts below 50% (R=0.24, P=0.05, Figure 2C). The most prominent 
differences were seen in the response to trametinib and venetoclax 
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(Supplemental Figure 3). The poor correlation was partly due to highly 
different drug sensitivities of the non-blast cell populations when compared to 
blasts as demonstrated in two samples with low blast counts (Figure 2 D-G). 
Our data shows that AML BM subpopulations have heterogeneous drug 
responses that confound the assessment of blast specific drug sensitivities 
when using homogenous cell viability assays in unsorted BM-MNC samples. 
 
Ex vivo drug screening predicts induction therapy response 
Next, we evaluated whether incomplete bone marrow blast clearance at 
d14/d28 after induction treatment was associated with decreased ex vivo drug 
sensitivity. We evaluated BM samples from 15 patients collected prior to 
anthracycline+cytarabine induction chemotherapy. Amongst these patients, 
five had >10% blast cells at d14 and/or d28 and were defined as 
chemoresistant as described in Supplemental Table S1. Additionally, we 
included samples from two patients resistant to induction (collected at the time 
of resistant disease) in the chemoresistant group. A combined DSS of 
cytarabine and idarubicin showed significantly lower values for the resistant 
patients both with FC and (P<0.05, 2H) and CTG (P<0.01, Figure 2I). 
Furthermore, we observed a significant difference between responders and 
non-responders when blast-specific idarubicin response was measured with 
FC (P<0.05, Figure 2H) or CTG (P<0.05, Figure 2I). These results are in line 
with a recent study demonstrating that a similar FC-based platform can 
predict induction therapy response in a larger AML cohort.25 
 
Blasts are highly sensitive to Bcl-2 inhibition whereas monocytes and 
granulocytes are resistant 
Using the FC approach, we were able to evaluate blast-specific drug 
responses and compare them to other cell types within the same or between 
samples. Amongst the seven tested drugs, venetoclax (IC50=3.0nM) and 
idarubicin (IC50=28.7nM) showed the highest toxicity against blasts (Table 1). 
However, between these two drugs venetoclax showed the most selective 
efficacy against blasts when compared to other cell populations and healthy 
CD34+ cells (Figure 3A, IC50 values in Supplemental Figure 4). Moreover, 
venetoclax was also effective against CD34+CD38- cells, which suggests 
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activity against leukemic stem cells (Supplemental Figure 5). Compared to 
blasts, monocytic cells (CD14+) were resistant to Bcl-2 inhibition (P<0.001, 
Mann Whitney U test), but sensitive to MEK and JAK inhibition (P<0.001, 
Figure 3A). The phenomenon was clearly observed in samples from patients 
diagnosed with acute monocytic leukemia (M5) that contained substantial 
fractions of both cell types (Figure 3 B-C). 
 
Overall BM AML sample sensitivity to venetoclax is associated with FAB 
subtype 
To follow-up on our findings, we hypothesized that AML samples with high 
monocytic cell content should have a distinct drug response profile when 
overall BM-MNC sensitivity is measured with the CTG assay. We re-analyzed 
our earlier published CTG-based drug sensitivity data of 37 AML samples 
comprised of FAB M1, M2, M4 and M5 samples that were screened with 296 
compounds.14,15 Amongst the 296 compounds, venetoclax showed the largest 
drug sensitivity difference between M1 and M5 AML (P<0.001, Supplemental 
Table 4, Figure 4A). Similarly, the CTG-based sensitivity of the AML sample 
cohort studied here showed a gradual decrease in venetoclax sensitivity from 
M0 towards M5 subtype (Figure 4B). When we limited our FC analysis to 
diagnostic samples, a significant but smaller difference in blast-specific 
venetoclax sensitivity was also associated with FAB subtype (P<0.05, Figure 
4C). This significance was not observed when we also included relapse and 
chemorefractory samples in the analysis (Figure 4D) largely due to a high 
number of chemorefractory M1/2 samples in our cohort that were more 
resistant to venetoclax (P<0.001, Figure 4 D-E). Taken together, monocytic 
cells blur the high blast specific venetoclax effect in Ficoll-enriched M4/5 
samples when measured with CTG but FAB subtype still has a significant 
effect on venetoclax response in blasts in our diagnosis AML sample cohort. 
 
FAB subtype is associated with BCL2 and MCL1 gene expression 
Anti-apoptotic Mcl-1 and Bcl-2 are considered the most important pro-survival 
factors in AML.26,27 Furthermore, their expression and phosphorylation has 
been shown to be regulated through the Ras/Raf/MEK/ERK, PI3K/PTEN/AKT 
and JAK/STAT signal transduction pathways in different leukemias.28–31 To 
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study whether the expression of BCL2 family members and activity of signal 
transduction pathways is associated with FAB subtypes, we analyzed gene 
expression data of MNCs of diagnosis AML samples using publicly available 
microarray and RNA-seq data. BCL2 was highly expressed in M0/1 AML and 
gradually decreased towards M5 samples and healthy monocytes (Figure 5A, 
Supplemental Figure S6). Notably, MCL1 showed an opposite trend in 
expression and was most highly expressed in healthy monocytes (Figure 5A). 
We also detected higher expression of BCL2A1, BCL2L11 (BIM), BID and 
JAK2 in M4/5 AML. A more detailed analysis of the healthy myeloid 
compartment revealed that BCL2 family expression is highly dependent on 
differentiation stage, which likely also influences the expression patterns seen 
between the different FAB subtypes (Figure 5B). Interestingly, high BCL2 and 
low MCL1 expression was also observed in FAB M3 AML and their heathy 
counterparts, colony forming unit (CFU) granulocytes (Figure 5A and 5B).  
High BCL2/MCL1 expression ratio in CFU granulocytes might explain the 
neutropenia seen in venetoclax treated patients. 
 
Next, we investigated whether common cytogenetic abnormalities (RUNX1-
RUNX1T1, CBFB-MYH11, MLL, PML-RARA) or mutations (FLT3, NPM1, 
RUNX1, CEBPA) explain some of the variation we observed in MCL1, BCL2 
or BCL-xL gene expression within FAB subgroups (Supplemental Figure 7). 
AML samples with RUNX1T1-RUNX1T1 fusions showed significantly different 
gene expression exclusively in the M2 subgroup and samples with MLL or 
CBFB-MYH11 fusions exclusively in the M4 subgroup (Figure 5C, 
Supplemental Table 5). Particularly, M4 samples with MLL fusions had high 
BCL2 but low MCL1 expression levels compared to other M4 samples. To 
assess whether major signal transduction pathways are differentially active in 
FAB subtypes, we performed gene set enrichment analysis (GSEA). The 
analysis revealed significant enrichment of gene sets associated with 
inflammatory signaling and IL6/JAK/STAT pathway in M4/5 AML (Figure 5 D-
E, Supplemental Table 6).  
 
To study whether ex vivo venetoclax response is associated with 
differentiation markers and BCL2 family expression, we analyzed the 
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published Beat AML data set which includes data from 562 AML patients.22 
Supporting our previous findings, samples that had high expression of 
monocytic/granulocytic cell markers (CD14, CD11b, CD86, CD68) were 
resistant to venetoclax (Figure 5F). High BCL2 expression was associated 
with venetoclax sensitivity whereas high MCL1 and BCL2A1 expression was 
associated with resistance (Figure 5F). These findings were also presented 
earlier by two different research groups.32,33  
 
Taken together, the gene expression data of mononuclear cell enriched AML 
samples indicate that M4/5 AML have low BCL2 but high MCL1 and BCL2A1 
expression and increased inflammatory signaling. Thus, the data support the 
decreased venetoclax sensitivity we observe with the total mononuclear cell 
fraction of M4/5 samples. 
 
MEK and JAK inhibitors sensitize venetoclax-resistant blast cells to 
venetoclax 
Next, we studied whether mutations might explain the observed differences in 
blast specific venetoclax responses, but did not find significant correlation 
between genetic lesions and venetoclax response in our limited patient cohort 
(Supplemental Table 7). However, as demonstrated earlier, we detected 
decreased venetoclax sensitivity in chemorefractory and M5 samples 
(Supplemental Table 7, Figure 4 A-E). When we divided the AML samples 
into two subgroups (sensitive DSS 21-43, IC50<20nM and resistant DSS 0-
21, IC50>20nM) from the mid-point of venetoclax response range, we noticed 
that resistant blasts were sensitive to either MEK and/or JAK inhibitors (Figure 
6A). This finding suggests that venetoclax resistant blasts are addicted to 
either JAK/STAT and/or MAPK pathways. Furthermore, venetoclax sensitive 
blasts were enriched for NPM1 (8/25 in sensitive vs. 1/8 in resistant) and 
IDH1/2 (10/25 in sensitive and 1/8 in resistant) mutations supporting the good 
clinical activity of venetoclax seen in this patient group (Figure 6A, 
Supplemental Table 7). 
 
To assess the efficacy and clinical relevancy of 27 drug combinations against 
blasts, we used concentrations achieved in patients’ plasma during treatment. 
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The results demonstrated prominent inter-patient variability with the most 
synergistic drug combinations when blast-specific drug responses were 
measured by FC (Supplemental Figure 8). Of the 27 tested drug 
combinations, venetoclax plus kinase inhibitors showed the highest average 
synergistic and blast killing effect (Table 2, higher BLISS score and lower 
mean % live blasts). Importantly, blasts were highly sensitive to single-agent 
venetoclax in 76% (25/33) of the samples with IC50<20nM. Thus, we did not 
observe synergy in the majority of the samples with a single venetoclax 
concentration of 50nM as this concentration alone was sufficient to kill the 
blasts (Figure 5A). To study the drug combination effect in more detail, we 
conducted additional drug testing of venetoclax with a more detailed 
concentration range on 4 AML samples. We observed that with lower 
venetoclax concentrations (10nM) a synergistic effect with MEK and/or JAK 
inhibitors was also detected in samples that were sensitive to single agent 
50nM venetoclax treatment (Supplemental Figure 9). 
 
Importantly, venetoclax (50nM) plus ruxolitinib (300nM) showed high efficacy 
(apoptosis/death>70%) and synergism in 6/8 venetoclax resistant samples 
(Figure 5A and 5B). Strikingly, by combining venetoclax (50nM) with 
trametinib (25nM), all venetoclax resistant blasts were effectively targeted 
(Figure 6A and 6B). Although the combinations showed substantial toxicity to 
healthy CD34+ cells, they targeted most effectively leukemic blasts (Figure 
6B). As a comparison, a drug combination used during induction treatment 
(cytarabine+idarubicin) showed remarkable inter-patient differences in blast 
toxicity and it was also toxic to healthy CD34+ cells (Figure 6B). Furthermore, 
the broad-spectrum tyrosine kinase and FLT3 inhibitor sunitinib (100nM) or 
mTOR inhibitor everolimus (10nM) were not as effective when combined with 
venetoclax (Figure 6A, Table 2). Our data demonstrate that by simultaneously 
inhibiting JAK and/or MEK signaling and Bcl-2, blast cells involving 
chemorefractory AML cells, can be effectively targeted ex vivo in 
physiologically relevant concentrations. 
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DISCUSSION  
With FC-based drug testing we were able to simultaneously measure drug 
sensitivities of different cell populations in primary AML BM samples. 
Monocytic cells abundantly present in FAB M4/5 AML were markedly resistant 
to Bcl-2 inhibitor venetoclax, while less differentiated blast cells in the same 
M4/5 samples or in M0/1/2 samples were sensitive. Accordingly, the overall 
BM MNC sensitivity to venetoclax was strongly influenced by FAB subtype. 
Our study shows that FC-based, phenotypic drug testing can improve the 
current understanding of ex vivo drug effects and may help to identify blast-
specific treatments for AML patients. 
 
Along with our previous studies, several other groups have evaluated ex vivo 
drug responses of Ficoll-enriched AML mononuclear cells using high-
throughput CTG or MTS based cell viability assays.14,34–36 While these assays 
provide fast and robust readouts they fail to accurately measure blast specific 
drug responses. By using more accurate microscopy based screening, Snijder 
et al. recently demonstrated that blast specific or relative blast fraction-based 
readouts increase predictive accuracy to treatment outcome.37 Similarly, 
Martinéz-Cuadrón et al. showed that a FC-based platform measuring blast 
specific effect in whole BM without MNC enrichment, predicted clinical 
response  to induction therapy.25 We also showed earlier that in chronic 
myeloid leukemia, CD34-depleted cells (mature granulopoietic cells) were 
insensitive to BCR-ABL-1 inhibitors ex vivo whereas CD34+ progenitor cells 
showed good sensitivity.38 In accordance, we demonstrate here with a FC-
based approach that blasts differ in their drug sensitivities in comparison to 
other cell populations in the same AML samples. The highest blast-specific 
efficacy was observed with venetoclax, whereas ruxolitinib and trametinib 
showed increased activity towards monocytic cells. Importantly, we 
demonstrate that in samples with low blast count, the overall mononuclear cell 
fraction sensitivity does not correlate well with the blast-specific drug 
sensitivity. 
 
Consistent with our results, earlier studies have shown that primary AML 
samples are sensitive to venetoclax ex vivo.15,39,40 Most of the studies have 
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used mononuclear cell fractions to assess cell viability and to measure protein 
and gene expression levels. We observed that mononuclear cells of M0/1 
samples that mainly consisted of blasts, were sensitive to venetoclax 
compared to mononuclear cells of M4/5 samples when using a homogenous 
CTG-based cell viability assay. Earlier, high ex vivo sensitivity to Bcl-2 
inhibition has been associated with M3 AML in a study by Niu et al., whereas 
Pan et al. found no associations with FAB subtypes.39,40 Importantly, both 
study cohorts lacked comprehensive spectra of different subtypes, with none 
or only one M0/1 AML case. To support our observation, mononuclear cells of 
M0/1 samples had a high BCL2/MCL1 gene expression ratio whereas M4/5 
samples had a low ratio. Increased Bcl-2 protein expression has also been 
reported in M0/1 AML,41 and increased Mcl-1 expression in M4/5 AML26 of 
which the latter has been linked to elevated Mcl-1 expression in differentiating 
monocytes.42 Accordingly, we observed high MCL1/BCL2A1 but low BCL2 
expression in healthy monocytic and granulocytic cell populations. 
 
By using a FC-based approach, we observed that several M5 samples 
contained venetoclax-sensitive blasts and a resistant monocytic cell fraction. 
This observation raises the question whether drug sensitivity profiling and 
gene/protein expression studies should focus on the immature blast cells and 
not the total MNC fraction especially in M4/5 samples. When we compared 
FC measured blast-specific venetoclax response between FAB subtypes, we 
observed a smaller but still significant difference between diagnosis M1 vs. 
M5 subgroups. In clinical trials, NPM1, IDH1/2 and RUNX1 mutations have 
shown to be promising biomarkers for venetoclax+HMA treatment.7,43 Based 
on a study analyzing genotype and FAB subtype-specific patterns of 4373 
adult de novo AML cases44, both IDH1/2 and RUNX1 mutations are enriched 
in M0/1/2 AML whereas NPM1 mutations are common in FAB M1/2/4/5 
subtypes. Therefore, patient cohorts with mutated IDH1/2 or RUNX1 may be 
skewed to contain larger numbers of FAB M0/1/2 samples. To identify 
responders, it might be useful to evaluate the combined genetic and cell 
phenotype/FAB subtype information in a clinical setting. 
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With the FC method we also looked for effective combinations, since only 
19% overall response rate was observed with venetoclax monotherapy in 
patients with high-risk relapsed/refractory (R/R) AML.6 In our study, all 
venetoclax-resistant blasts showed sensitivity to MEK and/or JAK inhibitors 
suggesting that JAK/STAT and MAPK pathways play a major role in 
venetoclax resistance. We showed earlier that stromal cell secreted cytokines 
such as GM-CSF mediate resistance to venetoclax, which can be 
counteracted by JAK inhibition.45 Moreover, the MAPK pathway plays a 
critical role in resistance through the proposed upregulation of MCL1.28 Both 
of these studies also demonstrated remarkable antileukemic activity in murine 
xenograft models when inhibiting JAK or MEK kinases together with Bcl-2. In 
agreement with the good synergism between ruxolitinib or trametinib with 
venetoclax observed here and in a recent study by the Beat AML study 
group,46 Kurtz et al. additionally showed that several different kinase inhibitors 
exhibited good synergism with venetoclax in AML samples.47 However, a 
recent clinical study with MEK inhibitor cobimetinib and venetoclax in R/R 
AML was closed due to limited clinical activity demonstrating that ex vivo drug 
screening results might not directly translate into clinical setting.48  
 
Inflammatory pathways are more active in M4/5 AML based on gene set 
enrichment analysis (GSEA), consistent with the observed high sensitivity of 
monocytic cells to ruxolitinib and trametinib. Earlier studies have 
demonstrated that leukemic cells of patients with M4/5 AML produce IL1/IL613 
and have higher proliferative activity in cytokine-free medium.49 Thus, 
secreted cytokines and culturing conditions may have a big role on the drug 
sensitivity profiles. While further investigation is warranted, results suggest 
that the JAK/STAT and MEK pathways are more active in differentiated 
monocytic cells as well as venetoclax resistant blasts.  
 
In summary, we show that ex vivo sensitivity of AML patient samples to 
venetoclax is associated with cell composition. Furthermore, we demonstrate 
that FC-based drug screening could be implemented to identify effective 
targeted drugs and drug combinations against immature blasts, accelerating 
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Table 1: Median drug sensitivity score (DSS) and IC50 values of the seven tested drugs against different cell populations 
  
Blasts (n=33) Monocytes (n=18) Lymphocytes (n=31) Granulocytes (n=5) 
  
DSS IC50 (nM) DSS IC50 (nM) DSS IC50 (nM) DSS IC50 (nM) 
  Median (Range) Median (Range) Median (Range) Median (Range) Median (Range) Median (Range) Median (Range) Median (Range) 
Venetoclax 27.1 (0-43) 3.0 (1-1000) 7.1 (0-29) 122.0 (1-1000) 18.1 (9-30) 20.3 (2-84) 5.7 (0.3-9) 113 (11-220) 
Idarubicin 22.0 (0-40.0) 28.7 (2-212) 16.1 (6-34) 78.7 (13-390) 16.5 (9-28) 84.0 (18-227) 19.0 (12-24) 41.1 (26-154) 
Cytarabine 9.7 (0-36) 894.2 (50-10000) 7.5 (0-23) 1071 (20-10000) 4.8 (0-10) 2550 (43-10000) 9.5 (4-19) 953 (305-1189) 
Ruxolitinib 5.0 (0-32) 302.7 (50-3000) 17.2 (0-37) 93.3 (60-2896) 0 (0-8) 2511 (99-10000) 0 (0.0-7) 2476 (246-3 000) 
Trametinib 3.0 (0-27) 18.9 (1-250) 25.9 (0-42) 2.4 (1-250) 0 (0-1) > 250 (7-250) 1.1 (0.0-7) 165 (15-250) 
Sunitinib 1.0 (0-17) 321.1 (8-1000) 5.7 (3-22) 223.7 (71-423) 0 (0-4) > 1000 (6-492) 4.4 (1-11) 352 (92-434) 




Table 2: Drug combination synergism and combination sensitivity in blasts 
    
# Drug I Drug II Drug III 
Mean BLISS 
score* 
Mean % of live 
blasts** 
1 Venetoclax 50nM Trametinib 25nM   0.083 11.3 
2 Cytarabine 300nM Trametinib 25nM   0.076 56.7 
3 Trametinib 25nM Everolimus 10nM   0.075 62.9 
4 Venetoclax 50nM Ruxolitinib 300nM   0.068 13.4 
5 Idarubicin 10nM Trametinib 25nM   0.057 51.3 
6 Trametinib 25nM Ruxolitinib 300nM   0.046 59.7 
7 Venetoclax 50nM Everolimus 10nM   0.040 18.6 
8 Sunitinib 100nM Trametinib 25nM   0.034 69.0 
9 Venetoclax 50nM Sunitinib 100nM   0.030 21.8 
10 Idarubicin 10nM Ruxolitinib 300nM   0.029 61.8 
11 Venetoclax 50nM Cytarabine 300nM   0.023 19.6 
12 Sunitinib 100nM Ruxolitinib 300nM   -0.004 73.3 
13 Sunitinib 100nM Everolimus 10nM   -0.001 80.8 
14 Everolimus 10nM Ruxolitinib 300nM   -0.018 73.9 
15 Cytarabine 300nM Sunitinib 100nM   -0.020 75.9 
16 Idarubicin 10nM Cytarabine 300nM   -0.026 64.9 
17 Idarubicin 30nM Cytarabine 1000nM   -0.029 40.1 
18 Idarubicin 10nM Everolimus 10nM   -0.038 69.5 
19 Cytarabine 300nM Everolimus 10nM   -0.046 80.1 
20 Everolimus 10nM Ruxolitinib 300nM Trametinib 25nM -0.051 52.4 
21 Cytarabine 300nM Ruxolitinib 300nM   -0.058 72.2 
22 Sunitinib 100nM Everolimus 10nM Ruxolitinib 300nM -0.067 63.8 
23 Idarubicin 10nM Ruxolitinib 300nM Trametinib 25nM -0.073 39.6 
24 Idarubicin 10nM Sunitinib 100nM   -0.088 74.7 
25 Cytarabine 300nM Ruxolitinib 300nM Everolimus 10nM -0.123 62.5 
26 Cytarabine 300nM Ruxolitinib 300nM Trametinib 25nM -0.129 54.4 
27 Idarubicin 10nM Ruxolitinib 300nM Everolimus 10nM -0.146 57.3 






Figure 1. Study outline and gating strategy. (A) Schematic outline of the 
experimental setup. (B) Gating strategy of cell populations. Dead and 
apoptotic cells were stained with 7-AAD and Annexin V, respectively, and 
cells negative to these markers were gated as live cells. CD45dim/SSClow 
and CD34+ population was used as the standard gate for AML blast cells. For 
samples with blast cells negative for CD34, CD45dim/SSClow and CD33 
positivity was used to identify blasts. Lymphocytes were gated based on 
CD45bright/SSClow and were confirmed to be CD33 negative. Immature 
granulocytes (present after Ficoll gradient centrifugation) were gated based 
on CD45dim/SSChigh, CD33+ and CD34-. Monocytes were identified based 
on CD14 positivity. Clinical immunophenotype data were obtained for all 
samples to validate the gated cell populations. The illustration shows patient 
sample 6323 at day 0. (C) Illustration of the immunophenotypic profiles of 
AML samples with different FAB subtypes and healthy bone marrow (BM) 
samples represented by CD45 vs. SSC plots at day 0. 
 
Figure 2. Comparison of flow cytometric (FC) and CellTiter-Glo (CTG) 
based drug screening approaches. (A) Spearman’s correlation between 
CTG and FC-based cell viability assays with CD45+ leukocytes as the FC 
readout, or (B) blasts in samples with clinical blast count >50%, or (C) blasts 
in samples with clinical blast count <50% as the FC readout. (D) 
Representative FC scatter plots of drug effects on different cell populations in 
AML sample 18 with low blast count (20%). Absolute cell counts inside the 
gates were calculated after 72h drug treatment and normalized to the cell 
counts in the DMSO-treated wells (represented as percentages). (E) 
Venetoclax dose response curves of different cell populations present in AML 
sample 18 assessed by FC and overall BM sensitivity with the CTG-based cell 
viability assay. (F) Representative FC scatter plots of drug effects on patient 
sample 5806 with acute monocytic leukemia (FAB M5). (G) Dose response 
curves of different cell populations after MEK inhibitor trametinib treatment 
calculated with FC or overall sensitivity calculated with CTG. (H) Comparison 
of the DSS values for idarubicin, cytarabine and idarubicin+cytarabine 
combination in blasts between induction treatment resistant and sensitive 
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patient samples using FC. (I) DSS measured with CTG from the same cohort. 
P-values calculated with Mann-Whitney U test. 
 
Figure 3. Maturation stage of AML cells affects drug sensitivities. (A) 
DSS values for distinct cell populations in 33 AML samples (blue) and 2-3 
healthy controls (orange). Cell population means were compared against 
blasts with Kruskal-Wallis test (Dunn’s test, *P<0.05, **P<0.001, 
***P<0.0001). HSPC=healthy hematopoietic stem/progenitor cells. (B) 
Representative FC scatter plots of the effects of venetoclax and trametinib on 
blasts, monocytic cells (CD14+) and lymphocytes after 72h drug treatment 
with the indicated concentrations. Absolute cell counts inside the gates were 
calculated after drug treatment and normalized to the cell counts in the 
DMSO-treatment wells (represented as percentages). (C) Inter- and intra-
patient comparison of the DSS values in blasts and monocytic cell fraction 
calculated with Mann-Whitney U test. 
 
Figure 4. Mononuclear cell (MNC) fraction sensitivity to venetoclax is 
dependent on FAB subtypes. (A) Venetoclax DSS values of AML samples 
with different FAB subtypes from an earlier published data set, and (B) from 
the present data set both measuring MNC fraction sensitivity with CTG based 
cell viability assay. (C) Blast-specific venetoclax sensitivity of diagnosis 
samples in FAB subgroups measured by FC from the present data set. (D) 
Blast-specific venetoclax sensitivity in different FAB subgroups measured by 
FC including chemorefractory and relapse samples. (E) Comparison of 
venetoclax DSS values between diagnosis, relapse and chemorefractory 
samples (induction resistant n=3, azacytidine resistant n=2). Black lines 
represent the mean of each subgroup. P-values calculated with the Kruskal-
Wallis (and Dunn’s) tests. 
 
Figure 5. Cell differentiation is associated with low BCL2 expression and 
venetoclax ex vivo resistance. (A) Heatmap of the median gene expression 
for each FAB class and control samples are shown for BCL2 family genes in 
the Hemap AML data set. Sample groups are ordered based on the 
differentiation state between HSCs (hematopoietic stem cells) and healthy 
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monocytes. Z-scores were used to define high and low expression categories. 
Z-scores were further discretized to low and high categories, defined as 
having Z-score cutoff over 2 for high and less than -2 for low expression. P-
values for FAB subgroup comparisons are presented in Supplemental Table 
5. Similar analysis for TCGA data set is presented in Supplemental Figure 6. 
(B) Heatmap of the median gene expression of BCL2 family genes for healthy 
hematopoietic cell types using Differentiation Map data set. (C) Significant 
BCL2, MCL1 or BCL-xL gene expression differences between samples with 
MLL, CBFB-MYH11 or RUNX1-RUNX1T1 fusion genes when compared to 
non-fusion gene containing samples in FAB M2 and M4 groups. Values 
obtained from the Hemap data set. * P-value<0.05, ** P-value<0.001. (D) 
Pathway enrichment results with normalized enrichment scores (NES) and 
significance as FDR q-value are shown for pathways upregulated in M4 and 
M5 samples when compared to M0 and M1 samples. Pathways consistently 
enriched in both Hemap and TCGA data sets are shown here, while full 
results are shown in Supplemental Table 6. (E) Heatmap of IL6-JAK-STAT3 
signaling pathway leading edge gene expression Z-scores using the Hemap 
data set. Z-scores were further discretized to low and high categories, defined 
as having Z-score cutoff over 2 for high and less than -2 for low expression. 
Samples are ordered based on FAB type. (F) Venetoclax drug response AUC 
and IC50 profiles, BCL2 family genes and differentiation marker gene 
expression value Z-scores and FAB subtypes are shown as a heatmap. 
Samples are ordered based on drug sensitivity with sensitive samples on the 
left and resistant on the right. Pearson correlation Rho and FDR value is 
shown for each gene. 
 
Figure 6. Inhibition of MEK and JAK pathways can overcome venetoclax 
resistance. (A) Heatmap showing characteristics of venetoclax sensitive 
(IC50<20nM, DSS>20) and resistant blasts (IC50>50nM, DSS<20) based on 
single agent venetoclax response measured by FC (top row). Blast-specific 
response of individual drugs is highlighted according to DSS values with red 
corresponding to high DSS value and blue to low DSS value. Blast-specific 
response to venetoclax combinations is highlighted according to percentage 
of apoptotic/dead cells with red corresponding to high percentage and blue to 
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low percentage of apoptotic/dead cells. The synergistic effect of the drug 
combination was assessed based on the BLISS synergistic score and is 
shown in the graph. Other characteristics covered include disease stage, 
molecular profiling, FAB subtype with M4 and M5 highlighted blue and FC-
determined blast percentage. Overall BM venetoclax sensitivity measured 
with CTG (bottom row) is used to demonstrate how low blast cell percentage 
affects DSS values when compared to blast-specific DSS values. 
D=Diagnosis, R=Relapse, Rf=Refractory, CL=CMML transitioned to AML. (B) 
Dot scatter plots of venetoclax (50nm) + ruxolitinib (300nM), venetoclax 
(50nM) + trametinib (25nM), and cytarabine (1000nM) + idarubicin (30nM) 
responses in healthy CD45+ leukocytes, granulopoietic cells, lymphocytes, 
monocytes and blasts. Dark blue dots represent single agent toxicity to blasts. 
Cell population means were compared against blasts with the Kruskal-Wallis 
test (Dunn’s test, *P<0.05, **P<0.001, ***P<0.0001). Orange dots represent 
healthy BM samples and light blue dots AML samples. Dark blue dots 
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Venetoclax 43 41 41 39 39 34 34 31 31 30 30 30 30 29 28 28 28 27 27 26 26 25 23 22 22 19 18 15 13 10 10 10 0
Ruxolitinib





Vene50+Trame25 0 60 100
Vene50+Eve10    N/A
Vene50+Ruxo300 0,0 0,0 0,0 0,0 0,0 0,1 0,0 0,1 0,1 -0,1 0,0 0,0 0,0 0,1 0,0 0,1 0,0 0,0 0,1 0,0 0,1 0,0 0,0 0,1 0,1 0,2 0,2 0,1 0,4 0,0 0,2 0,3 0,1  BLISS synergy score
Vene50+Trame25 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,1 0,0 0,0 0,0 -0,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,1 0,1 0,0 0,1 0,0 0,1 0,1 0,3 0,4 0,2 0,5 0,4 0,1








FAB subtype M2 M1 M1 M1 M1 M1 M2 M5 M2 M1 M3 M1 CL ? M5 M2 M1 M5 M2 M2 M2 M5 M1 M0 M0 M1 M5 M5 M2 M5 M2 M4 M1
Blast % 85 85 92 36 82 85 31 35 96 60 86 79 23 57 48 43 78 33 83 61 54 25 53 83 62 86 24 63 47 N/A 17 90 56










































Phenotype-based drug screening reveals an association between 
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BM samples of 34 AML patients and three healthy volunteers were obtained from Helsinki 
University Hospital Comprehensive Cancer Center after informed consent (permit 
numbers 239/13/03/00/2010, 303/13/03/01/2011, Helsinki University Hospital Ethics 
Committee) and in compliance with the Declaration of Helsinki. Cytogenetic analysis was 
performed at hospital laboratories by fluorescence in situ hybridization and chromosomal 
banding analysis. Exome sequencing was performed as earlier described.1 Patient 
characteristics are presented in Supplemental Table 1.  
 
 
Preparation of drug plates 
The compounds (Supplemental Table 2) were dissolved in 100% DMSO and dispensed 
on 96-well V-bottom plates (Thermo Fisher Scientific, Carlsbad, CA) and 384-well plates 
(Corning, Corning, NY) using an acoustic liquid handling device Echo 550 (Labcyte, 
Sunnyvale, CA). The plates contained several DMSO controls, 7 drugs (1,000-10,000-
fold dilution series) and 27 drug combinations with one chosen concentration for each 
drug. Drug plate layouts and concentrations are presented in Supplemental Figure 1. 
 
BM mononuclear cells (BM-MNCs) were isolated using Ficoll-Paque Premium (GE 
Healthcare, Little Chalfont, Buckinhamshire, UK) density gradient centrifugation. Fresh 
BM-MNCs were suspended in mononuclear cell medium (MCM; PromoCell, Heidelberg, 
Germany) supplemented with 10 μg/mL gentamicin and 2.5 μg/mL amphotericin B and 
plated in parallel on pre-drugged 96-well plates (100,000 cells/well in 100 μl) for FC 
analysis and 384-well plates (10,000 cells/well in 25 μl) for CTG-based cell viability assay. 
The cells were incubated with the drugs for 3 days at 37°C and 5% CO2. Eleven of the 34 
AML samples were viably frozen. Cells were treated with DNase I after thawing and after 
washing dispensed on the drug plates. 
 
Flow cytometry-based readouts 
Following 72h incubation with the drugs, cells were centrifuged (500xg, 6 min) in the 96-
well plates and media discarded by inverting the plates. Cells were suspended in 25 μL 
of antibody mix containing staining buffer (10% FBS and 0.02% NaN3 in RPMI-1640 
medium) and the following antibodies: BD Biosciences (Santa Jose, CA): CD33 (BV421, 
clone WM53, dilution 1:600), CD45 (BV786, clone HI30, 1:50), CD34 (PE-Cy7, clone 
8G12, 1:50), CD14 (APC, clone M5E2, 1:100) and Cytogonos (Salamanca, Spain): CD38 
(FITC, clone LD38, 1:50). Cells were stained for 30 min at room temperature (RT) in the 
dark and subsequently washed with 100 μL staining buffer followed by centrifugation 
(500xg, 6 min) and supernatant removal. Apoptotic and dead cells were discriminated by 
7-aminoactinomycin D (7-AAD) and PE-Annexin V (BD Biosciences) staining with both 
dyes diluted 1:50 in 25 μL Annexin V binding buffer. The plates were incubated for 20 min 
at RT before FC analysis. FC analysis was performed using the iQue Screener PLUS 
instrument (Intellicyt, Albuquerque, NM). All media/cells were extracted from each well 
using 16 s sip time/well and pump speed of 32 rpm resulting in 35 min reading time for a 
96-well plate. ForeCyt software (Intellicyt) was used to gate cells and acquire population 
counts. Analysis was done from viable CD45 positive singlet cells and the gating strategy 
is illustrated in manuscript Figure 1B. The cell count of a well was normalized to its 6 
adjacent DMSO controls. 
 
Data sets 
Gene expression was analyzed from AML microarray data (log2 expression) from the 
Hemap data set (http://hemap.uta.fi/)2,3 and TCGA RNA-seq data (RSEM values) 
generated by the TCGA Research Network (http://cancergenome.nih.gov/).4 The data 
were generated using RNA extracted from the mononuclear cell fraction of AML patients. 
Beat AML RNA-seq count matrix was obtained from the authors (Tyner 2018).5 Genes 
with expression > 1 cpm in more than 1 % of samples were kept and data were normalized 
using limma voom and quantile normalization. Beat AML ex vivo drug sensitivity data was 
obtained from Supplemental Table 41586_2018_623_MOESM3_ESM.xlsx (Tyner 2018). 
For analysis of gene expression in healthy hematopoietic cell types Differentiation Map 
data was used.6 
 
Gene expression analysis 
The two-tailed Wilcoxon test followed by Benjamini-Hochberg adjustment of P-values and 
fold change was computed to compare gene expression levels for BCL2, BCL2L1, 
BCL2A1, MCL1, BCL2L2, BCL2L11, BID, BBC3, BAX, BAK1, BOK, B2M, and JAK2. 
Comparisons were first done between FAB M0, M1, and M2 groups to M3, M4, and M5 
groups individually for each BCL2 family gene. Fusion gene status for RUNX1-RUNX1T1, 
CBFB-MYH11, MLL, PML-RARA, mutation status of FLT3, NPM1, RUNX1, CEBPA, plus 
complex and normal karyotype groups were next tested within each FAB group to 
investigate whether these events could explain some of the variance observed in BCL2, 
BCL2L1 and MCL1 expression levels. 
 
For analysis of gene expression in hematopoietic cell types using Differentiation Map 
data,6 log2-transformed expression values of Affymetrix HG_U133AAofAv2 probe sets 
were downloaded from GEO (GSE24759). Affymetrix probe set identifiers were converted 
to gene symbols using biomaRt7 and probes representing the same gene were averaged 
to obtain expression values for each gene. Heatmap of selected genes was plotted using 
Z-scores across median expression values of myeloid and stem cell populations. 
 
Analysis of venetoclax drug sensitivity and BCL2 family gene expression in Beat 
AML data set 
Pearson correlation and correlation test of significance was computed for venetoclax AUC 
drug response values and BCL2 family and differentiation markers CD14, CD11b, CD68, 
CD86, CD15, CD36, CD38, CD34 gene expression values. NA values were omitted and 
P-values were adjusted using the Benjamini-Hochberg method. 
 
Pathway analysis 
The command line version of GSEA8 was used to perform gene set enrichment analysis 
comparing combined M0, M1 to M4, and M5 FAB group pathway profiles. Log2 expression 
values for Hemap and RSEM values for TCGA AML data sets were used in the analysis. 
Sample permutation and multiple hypotheses testing correction were used to obtain FDR 
q-values. Gene sets used in the analysis included KEGG, Biocarta, Hallmarks, Reactome 
from MsigDB v5.0, Wikipathways (06.2015) and PID V4. FDR q-values below 0.1 were 
defined as significant.
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Diagnosis (ICD-O) Risk class at the time of diagnosis



































1 BM 1399_3 Frozen CMML Acute monocytic leukemia Intermediate Refractory 2 M5 Trisomy 19 KRAS, NRAS Cytarabine + Idarubicin 10 30 40 Res 30 31 61 6 10 16
2 BM 3443_6 Frozen No Acute myeloid leukemia without maturation High Refractory 4 M1 At diagnosis, del 17p, -2 (both), -17 (both), -5, -6, -7, -11, -12, -18, -22, +13,+21, 6-8 marker chromosomesNone Cytarabine + Idarubicin 79 1 60 Res 0 19 19 0 10 10
3 BM 997_1 Frozen No Acute myeloid leukemia with maturation Intermediate Diagnosis 0 M2 Normal NA Hydroxyurea 90 NA NA 23 33 56 18 34 52
4 PB 2791_7 Frozen Breast cancer Therapy-related acute myeloid leukemia High Relapse 15 M1 NA FLT3-ITD Cytarabine + Idarubicin 90 <5 1 8 28 36 8 29 37
5 BM 1690_2 Frozen No Acute myeloid leukemia without maturation Intermediate Diagnosis 0 M1 Normal IDH2, NPM1, FLT3-ITD Cytarabine + Idarubicin 90 <5 1 Sens 11 23 34 3 14 17
6 BM 4374_2 Frozen No Acute myelomonocytic leukemia Low Diagnosis 0 M4 Normal DNMT3, NRAS Cytarabine + Idarubicin 50 1 1 Sens 36 35 71 26 33 59
7 BM 18 Fresh CMML AML/CMML Relapse CMML/M1 NA IDH2, DNMT3, ASXL1 NA NA NA NA 7 18 25 3 13 16
8 BM 2686_4 Fresh No Acute myeloid leukemia with maturation Intermediate Refractory* 45 M2 Normal IDH2 Cytarabine + Idarubicin 42 4 4 14 14 28 9 20 29
9 BM 6333_3 Frozen NHL Acute myeloid leukemia without maturation Low Refractory M1 Normal NPM1, TET2 Azacitidine 70 42 7 25 32 8 17 25
10 BM 5250_4 Fresh MDS Acute myeloid leukemia with maturation High Refractory M2 46;XX;del(5q);-21;+der(21); TP53 Azacitidine 8 7 7 14 21 1 10 11
11 BM 6532_2 Fresh Breast cancer Acute monocytic leukemia Intermediate Diagnosis 0 M5b Normal FGFR4, TET2 Cytarabine + Idarubicin 45 1 Sens 13 22 35 6 19 25
12 BM 6545_2 Fresh No Acute leukemia with mnimal differentation Intermediate Diagnosis 0 M0 46;XY;del(6q);del(12q); DNMT3, IDH2 Hydroxyurea 85 NA 4 19 23 4 26 30
13 PB 17 Fresh MDS Acute myeloid leukemia without maturation Relapse M1 NA SETBP1, NRAS, EZH2, DDX41, ASXL1 Cytarabine + Daunorubicin NA NA NA 19 31 50 12 28 40
14 BM 6565_3 Fresh Endometrium ca Acute myeloid leukemia without maturation Intermediate Diagnosis 0 M1 47;XX;+8;abn(22) (14/20) / 46;XX (6/20) IDH2, DNMT3 Azacitidine 46 7 15 22 4 16 20
15 BM 6576_2 Fresh No Acute myeloid leukemia without maturation Intermediate Diagnosis 0 M1 NA IDH2, FLT3 Cytarabine + Idarubicin + Lenalinomide 80 <5 <5 Sens 12 34 46 15 29 44
16 BM 6598_2 Fresh Prostata ca Acute myeloid leukemia without maturation Intermediate Diagnosis 0 M1 Normal CEBPA, TET2 Azacitidine 70 1 1 12 40 52 7 14 21
17 BM 6525_2 Fresh MDS Acute monocytic leukemia Intermediate Diagnosis 0 M5b 46;XY;del(9q) (5/20) / 46;XY (15/20) FLT3-ITD Cytarabine + Idarubicin 65 27 10 Res 14 28 42 8 13 21
18 BM 6641_2 Fresh Prostata ca Acute myeloid leukemia with maturation High Diagnosis 0 M2 Normal IDH1, ASXL, BCOR Cytarabine + Idarubicin/Daunorubicin 42 38 2 Res 10 15 25 6 13 19
19 BM 6637_4 Frozen No Acute monocytic leukemia High Relapse 3 M5a 47;XY;+i(5p);-7;+8 / 46;XY; FLT3, NPM1 Cytarabine + Idarubicin 84 0 3 6 13 19 13 13 26
20 BM 6688_2 Fresh No Acute myeloid leukemia with maturation High Diagnosis 0 M2 47;XY;+8 (13/20) / 46;XY (7/20) U2AF1, ASXL1, IDH1 Azacitidine 50 51 49 6 19 25 8 16 24
21 BM 6703_2 Fresh No Acute promyelocytic leukemia Low Diagnosis 0 M3 46;XY;t(15;17) (2/20) / 46;XY (18/20) NA ATRA 60 NA NA 1 20 21 3 18 21
22 BM 12 Fresh MDS Acute myeloid leukemia without maturation Relapse M2 46;XX;del(5q);(del7q) NA NA NA NA NA 3 10 13 1 7 8
23 BM 6730_2 Fresh No Acute myeloid leukemia without maturation High Diagnosis 0 M1 47; XX t(11q23) (MLL-gene) (7/20); 47; XX +21 (2/20); 47; XX (11/20)FLT3-ITD Cytarabine + Idarubicin + Lenalinomide 85 NA 2 Sens 16 27 43 14 30 44
24 BM 3708_3 Fresh No Acute myeloid leukemia with maturation Low Relapse 9 M2 45;X;-X;del(6q);rob(13;14);+ marker chromosomeCEBPA, CSFR8, IDH2, NPM1 Cytarabine + Idarubicin 65 0 1 11 23 34 11 27 38
25 BM 5806_2 Frozen No Acute monocytic leukemia Low Diagnosis 0 M5 Normal PTPN11, TET2, NPM1 Cytarabine + Idarubicin 41 <5 1 Sens 19 26 45 16 14 30
26 BM 4401_2 Frozen No Acute monocytic leukemia Intermediate Diagnosis 0 M5 Normal FLT3-ITD, NPM1 Cytarabine + Idarubicin 65 <5 Sens 3 22 25 15 11 26
27 BM 6834_2 Frozen No Acute monocytic leukemia Intermediate Diagnosis 0 M5b Normal NPM1 Cytarabine + Idarubicin 70 <5 Sens 11 26 37 9 12 21
28 BM 6862_2 Fresh No AML inv(16)(p13.1q22) Low Relapse NA NA KIT Cytarabine + Daunorubicin 61 <5 <5 13 22 35 16 21 37
29 BM 6911_2 Fresh No Acute myeloid leukemia with maturation Intermediate Diagnosis 0 M2 Normal NPM1, CEBPA Cytarabine + Idarubicin 63 5 1 Sens 28 33 61 13 22 35
30 BM 6940_2 Fresh No Acute leukemia with mnimal differentation Intermediate Diagnosis 0 M0 Normal IDH2 Cytarabine + Idarubicin 75 10 36 Res 0 15 15 1 17 18
31 BM 6323_3 Fresh No Acute myeloid leukemia with maturation Intermediate Relapse** 10 M2 Normal WT1, NRAS, FLT3-ITD Cytarabine + Idarubicin 24 19 12 Res 10 21 31 6 14 20
32 BM 6999_2 Fresh No Acute myeloid leukemia without maturation Low Diagnosis 0 M1 46; XY; -7, -21, +2 marker chromosomes NPM1, IDH2, DNMT3 Cytarabine + Idarubicin 91 <5 4 Sens 10 36 46 7 31 38
33 BM 7011_2 Fresh No MPAL (Myel 93%, B 7%) High Diagnosis 0 M2 Normal None Cytarabine + Idarubicin 62 74 NA Res 0 10 10 4 14 18
34 BM 3724_2 Fresh MDS AML with multilineage dysplasia Intermediate Diagnosis 0 Mult. Dysp Normal TET2, RUNX1, SRSF2, NSD1 Azacitidine 35 NA NA NA NA NA NA NA NA
*Refractory to Cytarabine+Idasanutlin
** 2nd induction treatment at the time of relapse
FC (DSS) CTG (DSS)
Supplemental Table S2. Compound list 
 
 
Drug name Mechanism/Targets Approvalstatus Supplier Supplier Ref Label name Solvent conc (nM)
Ruxolitinib JAK1&2 inhibitor Approved ChemieTek CT-INCB INCB018424(free base, Ruxolitinib) DMSO 10-3000
Trametinib MEK1/2 inhibitor Approved ChemieTek CT-GSK112 GSK1120212 DMSO 0.25-250
Sunitinib Broad TK inhibitor Approved LC Laboratories S-8803 Sunitinib maleate(Sutent, SU-11248) DMSO 0.1-1000
Everolimus binds FKBP12,causes inhibition of mTORC1 Approved LC Laboratories E-4040 Everolimus DMSO 0.1-100
Idarubicin Topoisomerase II inhibitor Approved Sigma-Aldrich I1656 Idarubicin HCl DMSO 1-1000
Cytarabine Anti-metabolite,interferes with DNA synthesis Approved
National Cancer
Institute NSC 63878-P/19 Cytarabine HCl DMSO 10-10000
Venetoclax Selective Bcl-2 inhibitor Approved ChemieTek CT-A199 ABT-199 DMSO 0.1-1000
Supplemental Table S3. Summary of the cell populations present in the BM  
samples at day 0 and day 3 
 
* Percentages were calculated from the CD45+ cell fraction and cell population smaller than 














N=34 Median (% of CD45+) Range (% of CD45+)
(n) Day0/Day3 Day0/Day3 Day0/Day3
Blasts (CD45dim/SSClow) 34/34 72/63 18-92
Blasts (CD34+) 21/21 55/56 10-86
Lymphocytes 33/33 7/7 1-49
Monocytes (CD14+) 17/18 4/8 0-61




















Supplemental Table S4.  Sensitivity of different FAB subtypes to 296 compounds 
# Drug DSS ( M1 vs. M5) M1 Mean (n=10) M2 Mean (n=16) M4 Mean (n=2) M5 mean (n=9) P value* FDR
1 Venetoclax 19,0 32,2 20,2 12,2 13,2 0,0005 0,075
2 Navitoclax 15,8 32,3 22,8 15,2 16,5 0,0011 0,103
3 (5Z)-7-Oxozeaenol 11,4 24,1 12,7 14,6 12,7 0,0004 0,075
4 Tipifarnib 8,8 19,1 10,9 11,1 10,3 0,0014 0,103
5 Quizartinib 8,0 13,9 2,0 5,4 5,9 0,1098 0,414
6 Vistusertib 7,8 19,6 11,2 16,2 11,7 0,0359 0,309
7 Ruboxistaurin 7,4 16,8 7,7 8,9 9,3 0,0052 0,218
8 Foretinib 7,0 15,7 3,5 9,0 8,7 0,1517 0,472
9 Idarubicin 7,0 23,4 18,4 19,2 16,4 0,0462 0,335
10 GSK650394 6,9 9,0 1,8 3,7 2,0 0,0112 0,224
11 Nintedanib 6,8 15,9 8,0 12,7 9,1 0,1285 0,432
12 Quisinostat 6,8 27,5 20,8 24,5 20,8 0,0129 0,224
13 Sunitinib 6,6 13,6 2,2 7,7 7,0 0,0897 0,395
14 AZD8055 6,4 21,7 11,2 15,7 15,3 0,1013 0,411
15 AZD7762 6,3 17,2 5,6 12,5 10,9 0,2460 0,534
16 Pictilisib 6,2 19,5 9,6 11,6 13,2 0,0407 0,334
17 Vorinostat 6,2 15,3 9,0 13,4 9,1 0,0038 0,218
18 Cabozantinib 6,2 9,4 1,6 3,9 3,3 0,0463 0,335
19 Teniposide 6,1 18,5 13,5 10,4 12,4 0,0247 0,271
20 Tamatinib 6,1 11,8 3,4 8,5 5,7 0,1154 0,427
21 Lestaurtinib 6,0 16,9 6,4 11,0 10,8 0,0458 0,335
22 Tacrolimus 6,0 7,4 1,5 0,8 1,3 0,0299 0,291
23 Panobinostat 5,9 27,8 21,7 26,0 21,9 0,0182 0,265
24 Nutlin-3 5,9 9,6 6,1 4,0 3,8 0,0115 0,224
25 Daunorubicin 5,9 17,7 14,7 12,7 11,8 0,0124 0,224
26 Sorafenib 5,8 8,1 0,5 1,9 2,3 0,1362 0,438
27 Belinostat 5,8 24,5 17,6 22,5 18,7 0,0051 0,218
28 Omipalisib 5,7 21,2 11,0 17,4 15,5 0,2098 0,511
29 Sapanisertib 5,6 17,7 8,3 10,0 12,1 0,0720 0,371
30 Ponatinib 5,6 17,3 5,6 14,8 11,7 0,1858 0,504
31 Mitoxantrone 5,5 11,7 6,8 5,4 6,1 0,0231 0,270
32 Tosedostat 5,2 8,7 3,7 7,3 3,4 0,0280 0,286
33 ZSTK474 5,2 20,7 11,5 13,7 15,5 0,1070 0,411
34 Crenolanib 5,1 15,8 6,4 13,1 10,7 0,2598 0,545
35 AZD1775 5,0 13,9 5,9 9,8 8,9 0,1041 0,411
36 Omacetaxine 5,0 36,5 31,9 34,2 31,5 0,1060 0,411
37 Idelalisib 4,9 13,3 4,8 4,4 8,4 0,1106 0,414
38 Everolimus 4,9 10,6 4,1 1,9 5,7 0,1959 0,504
39 BMS-754807 4,9 11,6 5,4 4,0 6,7 0,1566 0,473
40 Tubastatin A 4,8 7,5 3,0 5,2 2,7 0,0166 0,259
41 Gandotinib 4,8 11,4 5,1 8,8 6,6 0,1267 0,432
42 Momelotinib 4,7 14,3 7,1 11,0 9,6 0,0530 0,344
43 Ipatasertib 4,7 8,1 3,4 7,9 3,3 0,0877 0,395
44 UCN-01 4,7 20,8 12,5 19,0 16,1 0,2374 0,534
45 APR-246 4,6 6,7 4,2 1,5 2,1 0,0198 0,265
46 Doramapimod 4,6 11,2 4,3 10,5 6,6 0,1588 0,475
47 Dexamethasone 4,6 7,4 8,4 2,6 2,8 0,1626 0,476
48 Dactolisib 4,5 11,8 6,7 10,4 7,3 0,0816 0,378
49 Tubacin 4,5 8,9 3,3 6,9 4,4 0,0080 0,218
50 8-chloro-adenosine 4,5 18,1 11,2 15,6 13,6 0,0721 0,371
51 AZ 3146 4,5 10,7 3,5 9,0 6,2 0,0813 0,378
52 GSK-J4 4,4 18,3 16,6 13,9 13,9 0,0086 0,218
53 PF 431396 4,4 12,1 6,6 10,7 7,7 0,0785 0,375
54 Alvocidib 4,3 25,8 21,0 25,5 21,5 0,0104 0,224
55 OSI-027 4,3 11,9 4,8 8,6 7,6 0,0726 0,371
56 Midostaurin 4,2 13,3 4,1 11,0 9,1 0,3589 0,625
57 Temsirolimus 4,1 9,0 3,6 8,0 4,9 0,2422 0,534
58 Vinblastine 4,1 9,6 7,7 8,3 5,5 0,0237 0,270
59 Mitomycin C 4,1 6,5 4,7 3,8 2,5 0,0200 0,265
60 Sonolisib 4,1 7,0 3,2 3,2 2,9 0,0151 0,248
 61 Rebastinib 4,0 5,0 0,0 0,3 1,0 0,0778 0,375
62 Carfilzomib 4,0 29,3 27,3 27,6 25,3 0,0304 0,291
63 Dinaciclib 4,0 26,8 23,4 28,9 22,8 0,0710 0,371
64 Valrubicin 4,0 16,0 13,8 11,8 12,0 0,0540 0,344
65 Serdemetan 4,0 11,1 7,6 6,4 7,1 0,0583 0,344
66 NVP-RAF265 3,9 9,8 4,8 6,7 5,9 0,1256 0,432
67 Azacitidine 3,8 6,0 2,0 5,9 2,2 0,0079 0,218
68 Unknown [FIMM003726]3,8 12,4 NA NA 8,6 0,5101 0,763
69 Palbociclib 3,8 8,8 3,7 8,5 5,0 0,0279 0,286
70 Ralimetinib 3,6 12,1 3,5 11,9 8,5 0,3327 0,600
71 BMS-911543 3,6 9,8 3,5 13,0 6,2 0,2442 0,534
72 Entinostat 3,6 12,3 7,0 13,7 8,7 0,1217 0,432
73 Regorafenib 3,6 13,0 5,6 10,4 9,4 0,2107 0,511
74 GSK269962 3,5 8,5 4,9 5,1 5,0 0,1183 0,432
75 Tandutinib 3,5 4,9 0,7 2,2 1,4 0,1222 0,432
76 AVN944 3,4 8,7 5,8 8,2 5,3 0,0930 0,399
77 Dovitinib 3,3 5,4 1,3 2,2 2,1 0,0605 0,344
78 Apitolisib 3,3 16,8 9,3 13,4 13,6 0,2479 0,534
79 Etoposide 3,2 7,7 6,8 5,3 4,5 0,0993 0,411
80 Vandetanib 3,2 3,9 0,4 0,9 0,7 0,0708 0,371
81 Erlotinib 3,2 6,1 2,3 4,6 2,9 0,0324 0,300
82 Methylprednisolone 3,2 6,0 6,2 6,6 2,8 0,2303 0,528
83 Canertinib 3,2 13,2 9,5 13,8 10,0 0,0572 0,344
84 Tanespimycin 3,1 18,8 12,3 22,4 15,7 0,3360 0,601
85 GSK2636771 3,1 5,7 1,5 4,2 2,6 0,1318 0,433
86 Mocetinostat 3,0 14,2 11,1 16,2 11,2 0,2083 0,511
87 Alvespimycin 3,0 14,6 8,9 14,5 11,6 0,1529 0,472
88 PF-3845 3,0 4,9 2,0 3,0 2,0 0,0088 0,218
89 Dacomitinib 2,9 6,0 1,7 4,4 3,1 0,0218 0,268
90 Melphalan 2,9 5,3 2,7 0,0 2,3 0,3371 0,601
91 Luminespib 2,9 24,5 17,0 27,5 21,6 0,3616 0,626
92 KX2-391 2,9 12,2 9,8 10,0 9,2 0,2350 0,534
93 Veliparib 2,9 3,4 0,7 0,5 0,6 0,0206 0,265
94 Linifanib 2,8 4,9 0,9 1,9 2,1 0,1766 0,493
95 Raloxifene 2,7 3,9 1,7 2,6 1,2 0,0510 0,344
96 Gefitinib 2,7 6,8 2,4 5,6 4,0 0,1003 0,411
97 Dactinomycin 2,7 24,3 22,9 25,1 21,6 0,2284 0,528
98 Doxorubicin 2,6 10,7 9,0 9,0 8,1 0,1792 0,496
99 Prednisolone 2,6 4,5 4,2 5,1 1,9 0,1836 0,503
100 TGX-221 2,6 7,0 2,3 4,2 4,4 0,1670 0,480
101 Fludarabine 2,5 13,6 11,1 14,0 11,1 0,0576 0,344
102 SGC0946 2,5 4,0 2,3 2,8 1,5 0,0365 0,309
103 Valproic acid 2,5 4,4 2,6 2,2 2,0 0,0765 0,375
104 Seliciclib 2,4 4,1 1,7 3,0 1,7 0,0557 0,344
105 VER 155008 2,4 7,4 3,4 7,6 5,0 0,1926 0,504
106 BIIB021 2,4 21,5 13,7 22,5 19,1 0,4969 0,760
107 AZD1480 2,4 5,0 1,8 3,7 2,6 0,1972 0,504
108 PF-04691502 2,3 24,1 16,3 21,3 21,8 0,5985 0,809
109 MK-2206 2,3 7,0 3,1 5,5 4,7 0,3583 0,625
110 PF-04708671 2,2 3,5 1,9 1,8 1,2 0,0746 0,374
111 Fasudil 2,2 5,9 2,4 3,1 3,6 0,2489 0,534
112 Cladribine 2,2 15,1 12,8 15,3 12,8 0,3229 0,600
113 Linsitinib 2,2 5,9 4,0 3,0 3,7 0,3403 0,603
114 Bleomycin 2,1 7,7 4,4 4,6 5,6 0,2409 0,534
115 Fostamatinib 2,0 8,1 2,7 8,3 6,2 0,4931 0,760
116 Afatinib 2,0 4,7 1,3 4,1 2,8 0,1490 0,469
117 Axitinib 1,8 7,7 4,2 5,4 5,9 0,5199 0,763
118 Ridaforolimus 1,7 7,1 4,2 4,4 5,4 0,5107 0,763
119 Plicamycin 1,7 17,2 18,9 16,8 15,5 0,7034 0,846
120 Clofarabine 1,6 23,8 22,3 25,2 22,2 0,5186 0,763
121 Tamoxifen 1,5 5,5 3,1 5,8 3,9 0,3134 0,600
122 PF-670462 1,5 4,7 2,3 5,9 3,2 0,5231 0,763
 123 Ibrutinib 1,5 2,3 1,3 0,5 0,8 0,1277 0,432
124 Finasteride 1,5 2,7 0,5 0,5 1,2 0,2290 0,528
125 Sotrastaurin 1,5 4,7 1,1 6,0 3,2 0,5684 0,782
126 Aminoglutethimide 1,5 1,5 0,0 0,0 0,0 0,2947 0,600
127 I-BET151 1,5 11,3 8,2 15,5 9,9 0,5146 0,763
128 Iniparib 1,4 1,5 1,0 0,3 0,1 0,1942 0,504
129 CUDC-101 1,4 19,3 14,6 25,0 17,9 0,5902 0,801
130 Neratinib 1,3 7,0 3,9 8,1 5,7 0,3678 0,629
131 Rabusertib 1,3 1,8 0,7 2,0 0,5 0,2128 0,512
132 RD162 1,3 2,1 1,2 0,3 0,8 0,1376 0,438
133 Lomeguatrib 1,3 1,5 0,3 0,1 0,3 0,0903 0,395
134 Pazopanib 1,2 6,6 2,3 5,9 5,3 0,6611 0,830
135 Ruxolitinib 1,2 7,2 4,1 8,2 6,0 0,6431 0,829
136 Lenalidomide 1,2 4,9 2,7 8,5 3,7 0,6180 0,824
137 Tepotinib 1,2 1,4 0,2 0,1 0,2 0,2480 0,534
138 PFI-1 1,1 7,1 4,4 10,8 6,0 0,5617 0,780
139 8-amino-adenosine 1,1 23,1 16,7 24,3 22,0 0,6315 0,829
140 Tretinoin 1,1 2,4 1,3 1,3 1,3 0,6590 0,830
141 Flutamide 1,1 1,2 0,5 0,9 0,2 0,0462 0,335
142 Tofacitinib 1,0 2,3 1,3 3,3 1,3 0,4838 0,752
143 Selumetinib 1,0 11,1 6,6 12,0 10,0 0,7605 0,881
144 IOX-2 1,0 1,7 1,6 0,6 0,7 0,2016 0,506
145 PAC-1 1,0 5,9 5,3 5,4 4,9 0,3732 0,635
146 AT 101 0,9 13,8 14,2 15,1 12,9 0,6602 0,830
147 Tacedinaline 0,9 1,5 0,6 0,1 0,6 0,3168 0,600
148 Chlorambucil 0,9 1,5 1,4 0,1 0,6 0,0908 0,395
149 Uramustine 0,9 1,3 0,6 0,2 0,4 0,3463 0,610
150 SB 743921 0,9 1,4 1,9 3,0 0,6 0,3044 0,600
151 Clomifene 0,8 5,6 3,5 8,2 4,8 0,5380 0,764
152 XAV-939 0,8 0,9 0,1 0,3 0,1 0,1920 0,504
153 AZD1152-HQPA 0,8 2,6 1,5 2,7 1,8 0,6619 0,830
154 JQ1 0,8 15,2 11,7 21,4 14,5 0,7849 0,896
155 Simvastatin 0,8 1,9 1,0 0,6 1,2 0,3675 0,629
156 Bosutinib 0,8 9,9 7,4 10,8 9,2 0,6822 0,837
157 Exemestane 0,7 1,9 1,1 3,1 1,1 0,3908 0,648
158 Buparlisib 0,7 12,5 6,7 8,2 11,7 0,8111 0,909
159 Bortezomib 0,7 28,7 27,5 29,4 28,0 0,6421 0,829
160 Dabrafenib 0,7 1,3 0,4 0,3 0,6 0,1606 0,475
161 Obatoclax 0,7 1,8 1,0 0,4 1,1 0,5553 0,779
162 Vincristine 0,6 7,7 7,5 10,2 7,1 0,7388 0,871
163 Thioguanine 0,6 2,0 2,1 2,3 1,4 0,5331 0,764
164 Mitotane 0,6 0,6 0,0 0,0 0,0 0,3121 0,600
165 Enzastaurin 0,6 0,8 0,4 0,0 0,2 0,4721 0,739
166 UNC0638 0,6 5,7 6,1 7,2 5,1 0,3912 0,648
167 Rofecoxib 0,6 0,6 0,0 0,0 0,0 0,1662 0,480
168 Nilutamide 0,6 1,1 0,6 0,5 0,5 0,5224 0,763
169 Amonafide 0,6 8,6 7,6 12,0 8,0 0,7087 0,846
170 C646 0,5 3,2 4,1 4,6 2,7 0,7060 0,846
171 Tivantinib 0,5 1,4 0,8 2,4 0,8 0,5353 0,764
172 UNC0642 0,5 5,7 5,4 7,7 5,2 0,4850 0,752
173 Olaparib 0,5 1,7 0,7 4,0 1,2 0,5621 0,780
174 Arsenic(III) oxide 0,5 0,6 0,1 0,0 0,1 0,2559 0,541
175 AT-406 0,5 2,8 1,8 4,0 2,3 0,7444 0,874
176 Vismodegib 0,4 0,7 0,1 0,0 0,3 0,3763 0,636
177 Perifosine 0,4 0,5 0,1 0,0 0,1 0,1051 0,411
178 Lasofoxifene 0,4 0,6 0,2 1,1 0,2 0,2928 0,600
179 Rucaparib 0,4 1,6 0,7 3,6 1,2 0,6643 0,830
180 Bimatoprost 0,4 0,5 0,1 0,0 0,1 0,2287 0,528
181 Bicalutamide 0,4 1,6 0,5 4,4 1,2 0,8001 0,904
182 Fulvestrant 0,4 2,5 0,6 2,5 2,1 0,7922 0,898
183 Toremifene 0,3 3,2 2,4 6,3 2,8 0,8039 0,905
184 Topotecan 0,3 9,2 9,3 12,4 8,9 0,8522 0,931
 185 Letrozole 0,3 0,7 0,3 1,2 0,3 0,6642 0,830
186 Binimetinib 0,3 6,8 4,6 6,4 6,5 0,9069 0,962
187 Brivanib 0,3 0,3 0,0 0,1702 0,485
188 Plerixafor 0,3 0,3 0,2 0,0 0,0 0,3306 0,600
189 MK-0752 0,3 0,3 0,2 0,0 0,0 0,3306 0,600
190 Volasertib 0,2 6,3 4,3 6,7 6,0 0,9005 0,962
191 Abiraterone 0,2 1,9 1,0 0,1 1,7 0,8969 0,962
192 UNC1215 0,2 0,2 0,5 0,0 0,0 0,3306 0,600
193 Anagrelide 0,2 0,4 0,1 0,0 0,2 0,6684 0,831
194 Chloroquine 0,2 9,1 8,6 9,7 8,9 0,9176 0,962
195 Vinorelbine 0,2 11,1 10,6 15,3 10,9 0,9433 0,973
196 Enzalutamide 0,2 1,2 0,6 1,3 1,0 0,8593 0,932
197 Levamisole 0,2 0,2 0,0 0,4005 0,655
198 Bendamustine 0,2 0,5 0,8 0,6 0,4 0,5852 0,798
199 Crizotinib 0,1 1,1 1,2 0,7 0,9 0,8447 0,931
200 Allopurinol 0,1 0,3 0,3 0,4 0,2 0,7603 0,881
201 2-methoxyestradiol 0,1 1,8 2,0 1,9 1,7 0,9003 0,962
202 PF-4800567 0,1 1,5 0,5 0,7 1,4 0,9087 0,962
203 Irinotecan 0,1 2,7 3,7 7,3 2,6 0,9481 0,974
204 Vemurafenib 0,1 1,4 0,8 1,3 1,3 0,9298 0,962
205 Sonidegib 0,1 0,5 0,6 2,5 0,5 0,9168 0,962
206 Sirolimus 0,1 4,9 2,6 6,3 4,8 0,9849 0,991
207 AZD4547 0,1 3,0 1,3 1,9 2,9 0,9638 0,984
208 Metformin 0,1 0,3 0,0 0,0 0,2 0,8563 0,932
209 CPI-613 0,1 0,1 0,1 0,1 0,0 0,5010 0,760
210 Galunisertib 0,0 0,0 0,0 0,3306 0,600
211 Streptozocin 0,0 0,3 0,0 0,0 0,2 0,9200 0,962
212 Megestrol acetate 0,0 1,1 1,7 3,1 1,1 0,9820 0,991
213 Mercaptopurine 0,0 0,0 0,8 0,2 0,0 0,9598 0,983
214 Fluorouracil 0,0 0,9 0,5 0,3 0,9 0,9980 0,998
215 Pentostatin 0,0 0,0 0,1 0,4 0,0 0,3306 0,600
216 Imiquimod 0,0 0,2 0,3 0,9 0,2 0,9229 0,962
217 Pemetrexed 0,0 0,0 1,3 0,0 0,0 0,3306 0,600
218 TAK-901 0,0 6,4 4,1 7,8 6,4 0,9873 0,991
219 Pilaralisib 0,0 2,5 1,8 2,8 2,6 0,9818 0,991
220 Lapatinib 0,0 0,0 0,1 0,0 0,1 0,5642 0,780
221 1-methyl-D-tryptophan0,0 0,3 0,2 0,0 0,3 0,8861 0,957
222 Anastrozole -0,1 0,0 0,1 0,3306 0,600
223 Pipobroman -0,1 0,0 0,2 0,2 0,1 0,1558 0,473
224 Bexarotene -0,1 2,3 1,9 2,0 2,3 0,9719 0,989
225 Methotrexate -0,1 0,1 1,8 0,0 0,2 0,6770 0,835
226 Ifosfamide -0,1 0,0 0,2 0,0 0,1 0,3306 0,600
227 Tarenflurbil -0,1 0,5 0,1 0,2 0,6 0,8258 0,922
228 Roxadustat -0,1 0,1 0,1 0,1 0,2 0,5008 0,760
229 Niraparib -0,2 2,0 1,0 4,0 2,1 0,8520 0,931
230 Deferoxamine -0,2 2,8 2,8 1,0 2,9 0,9285 0,962
231 Estramustine -0,2 0,0 0,4 0,0 0,2 0,1732 0,488
232 Temozolomide -0,2 0,0 0,2 0,8 0,2 0,1242 0,432
233 15D-PGJ2 -0,3 0,0 0,1 0,8 0,3 0,1971 0,504
234 AT9283 -0,3 1,6 0,9 3,3 1,9 0,8379 0,931
235 Pravastatin -0,3 0,5 0,7 0,0 0,8 0,5810 0,796
236 Cytarabine -0,3 10,0 9,1 15,4 10,3 0,8438 0,931
237 VX-11E -0,3 3,0 2,6 5,3 3,3 0,7713 0,885
238 Hydroxyurea -0,3 0,1 0,1 0,7 0,5 0,3862 0,648
239 Fingolimod -0,3 6,1 6,5 7,6 6,4 0,6440 0,829
240 GSK343 -0,3 2,7 2,7 3,5 3,0 0,7868 0,896
241 Ixabepilone -0,4 0,3 0,6 1,1 0,7 0,3256 0,600
242 Celecoxib -0,4 0,3 0,1 2,1 0,7 0,4031 0,656
243 Cyclophosphamide -0,4 0,0 0,0 0,0 0,4 0,3306 0,600
244 Goserelin -0,4 0,4 0,1 0,0 0,8 0,4284 0,682
245 Sepantronium bromide-0,4 19,2 22,6 22,7 19,6 0,9187 0,962
246 Carboplatin -0,5 2,9 4,0 4,2 3,4 0,7345 0,870
  
 
247 4-hydroxytamoxifen -0,5 4,1 4,4 6,0 4,5 0,7078 0,846
248 Altretamine -0,5 0,0 0,0 2,6 0,5 0,3306 0,600
249 Vatalanib -0,5 1,0 0,8 0,9 1,5 0,6559 0,830
250 Thalidomide -0,5 0,0 0,1 2,1 0,6 0,1992 0,504
251 Stattic -0,6 16,1 15,2 21,4 16,7 0,7563 0,881
252 Thio-TEPA -0,6 0,7 0,8 0,5 1,3 0,5137 0,763
253 Carmustine -0,6 0,2 0,2 1,9 0,8 0,2040 0,507
254 Busulfan -0,6 0,9 0,4 2,8 1,6 0,5368 0,764
255 Nelarabine -0,7 4,2 6,7 7,0 4,9 0,6925 0,844
256 Atorvastatin -0,7 4,9 5,1 5,3 5,7 0,6324 0,829
257 Bryostatin 1 -0,7 1,2 1,5 0,4 1,9 0,6840 0,837
258 Varespladib -0,7 0,1 0,1 0,0 0,8 0,1308 0,433
259 Nilotinib -0,8 5,9 3,4 9,7 6,7 0,7619 0,881
260 SNS-032 -0,8 29,9 27,6 35,0 30,7 0,8509 0,931
261 StemRegenin 1 -0,8 1,1 1,2 4,5 1,9 0,4693 0,739
262 Infigratinib -0,8 0,1 0,5 1,6 1,0 0,0551 0,344
263 BI 2536 -0,9 6,8 6,0 10,0 7,6 0,6436 0,829
264 Decitabine -0,9 1,1 1,6 1,2 1,9 0,3916 0,648
265 Refametinib -0,9 12,5 9,1 14,3 13,4 0,7685 0,885
266 Galiellalactone -0,9 3,6 2,9 6,5 4,5 0,5466 0,770
267 Prednisone -1,0 0,0 0,2 4,5 1,0 0,2231 0,528
268 Auranofin -1,0 5,3 6,6 7,6 6,3 0,6061 0,812
269 Floxuridine -1,1 0,0 1,7 1,3 1,1 0,0604 0,344
270 Imatinib -1,2 2,4 2,4 3,6 3,6 0,6052 0,812
271 Capecitabine -1,2 0,0 0,0 6,0 1,2 0,3281 0,600
272 Masitinib -1,2 5,6 3,9 6,4 6,8 0,6757 0,835
273 PF-00477736 -1,2 8,8 5,0 12,8 10,1 0,7056 0,846
274 Tivozanib -1,3 9,0 4,8 10,7 10,3 0,7238 0,860
275 Mechlorethamine -1,4 1,3 0,8 3,3 2,7 0,1341 0,436
276 Motesanib -1,4 2,0 1,2 2,8 3,4 0,5354 0,764
277 Cediranib -1,5 0,0 0,3 2,5 1,5 0,1060 0,411
278 Danusertib -1,6 6,1 4,6 9,1 7,7 0,4569 0,723
279 Saracatinib -1,7 3,9 2,0 8,7 5,5 0,4250 0,680
280 Trametinib -1,7 9,3 6,7 13,1 11,1 0,6263 0,829
281 Oxaliplatin -1,9 9,8 10,7 18,1 11,7 0,6365 0,829
282 ABT-751 -1,9 3,9 3,9 11,1 5,8 0,2510 0,535
283 Cisplatin -2,0 3,3 5,0 7,1 5,3 0,2949 0,600
284 Camptothecin -2,1 7,6 9,0 15,3 9,7 0,3137 0,600
285 Gemcitabine -2,1 4,5 6,0 8,7 6,7 0,2626 0,547
286 Indibulin -2,3 0,4 2,3 6,0 2,7 0,0344 0,309
287 Dasatinib -2,3 7,2 5,0 12,7 9,5 0,5397 0,764
288 Alisertib -2,4 3,5 3,7 3,7 5,9 0,1989 0,504
289 TAK-733 -2,7 7,6 6,2 13,6 10,3 0,4251 0,680
290 Pimasertib -2,9 10,8 8,9 15,0 13,8 0,4118 0,666
291 Patupilone -3,5 1,8 4,5 9,2 5,2 0,0574 0,344
292 Daporinad -3,7 19,3 16,4 35,1 23,0 0,3978 0,654
293 Mepacrine -4,5 8,5 12,7 17,9 12,9 0,2282 0,528
294 Pevonedistat -4,7 4,3 6,0 17,4 9,0 0,0682 0,371
295 Docetaxel -5,2 2,2 5,9 10,8 7,5 0,0456 0,335
296 Paclitaxel -5,9 2,7 4,7 8,0 8,6 0,0082 0,218
*P-value calculated from M1 vs. M5 data set
• Mean AML sample sensitivities to individual drugs of different FAB subtypes. Earlier published data of 37 AML samples 
screened with 296 compounds and cell viability measured with CTG were re-analyzed and the mean DSS values 
calculated. The difference between mean DSS values of M1 and M5 subtypes was calculated with Student’s t-test (two-
sample, unpaired). The Benjamini-Hochberg method was used to adjust P-values.
• The venetoclax concentration range used in the earlier study was 1-10 000nM compared to 0.1-1 000nM range used in 
this study.
Supplemental Table S5.  Differential BCL2 family gene expression values and P-











































Mutations FLT3, NPM1, RUNX1, CEBPA Wild Type (wt)
Fusion genes RUNX1-RUNX1T1, CBFB-MYH11, MLL, PML-RARA Wild Type (wt)
Karyotype Complex Karyotype, Normal Karyotype Rest of the samples
Each feature above was tested within FAB group, for example FLT3mut M0 vs FLT3wt M0
a-b: Significant genes between M4-M5 and M0-M1
c-d: Significant genes between M0 to M5 genetic subtype
TCGA_AML_statistics_M0_to_M5
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a. TCGA AML statistics M0 to M5
gene Fold	Change P-Value GroupA GroupB adj.	P-Value
MCL1 0.72440113623124 0.048 M3 M4 0.0713142857142857
MCL1 0.67384379952626 0.017 M3 M5 0.0285161290322581
MCL1 0.597334564870145 0.012 M0 M5 0.0211525423728814
MCL1 0.631354136387117 0.011 M2 M5 0.0200701754385965
MCL1 0.678723547036657 0,03 M2 M4 0.00863396226415094
MCL1 0.642151545812753 0,03 M0 M4 0.00856470588235294
JAK2 0.773888815346665 0.033 M0 M4 0.052
JAK2 0.699606396318039 0.011 M2 M5 0.0200701754385965
JAK2 0.679568306951877 0,01 M1 M5 0.00455
JAK2 0.499076657371927 0.000013 M3 M5 0.0000614545454545454
JAK2 0.600471536254176 0.000009 M2 M4 0.000052
JAK2 0.583272862301762 0.0000021 M1 M4 0.00001456
JAK2 0.428357042957174 0.00000021 M3 M4 0.00000312
BOK 1.54184627027858 0.045 M3 M4 0.0678260869565217
BID 0.813289987666822 0,01 M2 M4 0.00354545454545455
BID 0.776599593468677 0.00041 M1 M4 0.00115243243243243
BID 0.685163233790136 0.000056 M0 M4 0.000215703703703704
BID 0.647843814892762 0.0000066 M2 M5 0.0000403764705882353
BID 0.684362276564345 0.0000063 M3 M4 0.0000403764705882353
BID 0.545781664515838 0.00000062 M0 M5 0.00000586181818181818
BID 0.618617284002548 0.00000057 M1 M5 0.00000586181818181818
BID 0.545143644630444 0.000000011 M3 M5 0.000000286
BCL2L11 0.571237226256204 0.00049 M1 M4 0.00130666666666667
BCL2L11 0.518313964432618 0.00045 M2 M4 0.00123157894736842
BCL2L11 0.459479190226749 0.000079 M1 M5 0.000273866666666667
BCL2L11 0.416909945140552 0.000071 M2 M5 0.000263714285714286
BCL2L11 0.439693357498595 0.000021 M3 M4 0.0000949565217391304
BCL2L11 0.475146610456495 0.000013 M0 M4 0.0000614545454545454
BCL2L11 0.353670836852854 0.0000019 M3 M5 0.0000141142857142857
BCL2L11 0.382187941851004 0.00000083 M0 M5 0.00000719333333333333
BCL2L1 1.41463723737829 0.027 M0 M4 0.043875
BCL2L1 1.40968712777108 0.025 M0 M5 0.0412698412698413
BCL2L1 1.41053072827582 0.015 M1 M5 0.026
BCL2L1 1.41548380018217 0,03 M1 M4 0.00863396226415094
BCL2L1 1.44531566059559 0,01 M2 M5 0.00429565217391304
BCL2L1 1.45039087962541 0.00069 M2 M4 0.001794
BCL2L1 1.77868680485133 0.00022 M3 M5 0.000653714285714286
BCL2L1 1.78493265505983 0.00011 M3 M4 0.000369032258064516
BCL2A1 0.445150499370007 0.039 M1 M5 0.0596470588235294
BCL2A1 0.16072427211598 0.00079 M3 M5 0.00200390243902439
BCL2A1 0.337025246228384 0.00018 M1 M4 0.000567272727272727
BCL2A1 0.121684997459121 9.7e-10 M3 M4 0.00000010088
BCL2 1.52880222775951 0,03 M3 M4 0.00943703703703704
BCL2 1.84192495804133 0,03 M0 M4 0.007904
BCL2 1.39104266197784 0,02 M1 M4 0.00530612244897959
BCL2 3.21292852946006 0.000054 M0 M5 0.000215703703703704
BCL2 2.18618354461221 0.000035 M2 M5 0.000151666666666667
BCL2 2.66673855089834 0.000013 M3 M5 0.0000614545454545454
BCL2 2.42644014070869 0.0000011 M1 M5 0.0000088
BBC3 0.531225691245345 0.002 M1 M5 0.00442553191489362
BBC3 0.460562893240659 0.00016 M2 M5 0.00052
BBC3 0.389527911000017 0.000054 M0 M5 0.000215703703703704
BAX 1.20608646064382 0.032 M1 M4 0.355555555555556
BAX 0.702687605752078 0,01 M0 M4 0.00354545454545455
BAX 0.660069790274895 0,00 M1 M5 0.00115243243243243
BAX 0.585123270193253 0.000078 M3 M5 0.000273866666666667
BAX 0.553893105953214 0.00000038 M2 M5 0.00000494
BAX 0.384568499599897 0.0000000036 M0 M5 0.0000001872
BAK1 0.76660312575102 0.017 M0 M4 0.0285161290322581
BAK1 0.713069343531053 0.00022 M3 M4 0.000653714285714286
BAK1 0.585381362174925 0.00000045 M2 M5 0.0000052
BAK1 0.57414068232008 0.00000017 M1 M5 0.00000294666666666667
BAK1 0.482835670297674 0.000000017 M0 M5 0.0000003536
BAK1 0.449118067598852 0.000000011 M3 M5 0.000000286
B2M 0.726301782391095 0.038 M2 M5 0.0589850746268657
B2M 0.621269729010482 0.012 M0 M5 0.0211525423728814
B2M 0.801357118148607 0.007 M2 M4 0.0132363636363636
B2M 0.685471152216891 0,01 M0 M4 0.00392888888888889
B2M 0.609466592436113 0.00089 M1 M5 0.00220380952380952





b. Hemap AML statistics M0 to M5
gene Fold	Change P-Value GroupA GroupB adj. P-Value
MCL1 0.756176785661429 0.022 Healthy_CD34 M4 0.0308571428571429
MCL1 0.897566303440181 0.014 M2 M5 0.0204324324324324
MCL1 0.824092344440203 0.0604166666666667 M3 M4 0.0132338028169014
MCL1 0.782532086129728 0.0305555555555556 M1 Monocyte 0.00714586466165414
MCL1 0.716764145897184 0.0131944444444444 Healthy_CD34 M5 0.00333658536585366
MCL1 0.781139882370789 0.00077 M3 M5 0.00140949152542373
MCL1 0.622786601933196 0.00022 Healthy_CD34 Monocyte 0.000448301886792453
MCL1 0.779883133564879 0.00013 M2 Monocyte 0.000278019801980198
MCL1 0.675073066525414 0.000012 M0 M4 0.000031609756097561
MCL1 0.678721802368145 0.000011 M3 Monocyte 0.0000297
MCL1 0.639887628291896 0.0000015 M0 M5 0.00000498461538461539
MCL1 0.555989643070353 0.000000011 M0 Monocyte 0.0000000495
MCL1 0.436369274334818 0.0000000031 AML_CD34 M4 0.0000000171692307692308
MCL1 0.413625300518563 4.7e-10 AML_CD34 M5 0.00000000290057142857143
MCL1 0.359393388826824 1.3e-11 AML_CD34 Monocyte 1.08e-10
JAK2 0.864378529268028 0.026 M0 M4 0.0357707006369427
JAK2 0.745111320985678 0.00012 M0 M5 0.000261818181818182
JAK2 0.627058275288162 0.000093 Healthy_CD34 M4 0.000207092783505155
JAK2 0.64363469166669 0.000054 M0 Monocyte 0.000124085106382979
JAK2 0.672356052923596 0.0000091 AML_CD34 M4 0.0000255272727272727
JAK2 0.774418232375781 0.0000078 M1 M4 0.0000221684210526316
JAK2 0.466920968078552 0.0000076 Healthy_CD34 Monocyte 0.000021888
JAK2 0.540536586708859 0.0000033 Healthy_CD34 M5 0.0000103304347826087
JAK2 0.500650659590277 0.00000027 AML_CD34 Monocyte 0.00000106036363636364
JAK2 0.579584163423004 0.00000015 AML_CD34 M5 0.000000611320754716981
JAK2 0.576648335583184 0.0000000058 M1 Monocyte 0.0000000284727272727273
JAK2 0.73146900693134 0.0000000035 M2 M4 0.0000000184390243902439
JAK2 0.667563772794714 0.0000000032 M1 M5 0.00000001728
JAK2 0.544667426131783 2.5e-11 M2 Monocyte 0.0000000002
JAK2 0.630540694337041 0.000000000001 M2 M5 9.81818181818182e-12
JAK2 0.408291720434451 0.000000000000009 M3 Monocyte 1.08e-13
JAK2 0.548321278188971 3.4e-16 M3 M4 5.24571428571429e-15
JAK2 0.472663744045003 2.2e-17 M3 M5 4.752e-16
BOK 0.960534983989802 0.041 M1 M4 0.05535
BOK 1.13706238658765 0.025 AML_CD34 M4 0.0348387096774194
BOK 0.907101817774019 0.013 Healthy_CD34 M4 0.0191020408163265
BOK 0.924643538260555 0.0388888888888889 M0 M5 0.00876521739130435
BOK 1.14933801920959 0.0229166666666667 AML_CD34 M5 0.00556875
BOK 0.916978474163954 0.0104166666666667 M3 Monocyte 0.00267768595041322
BOK 0.914767780048233 0.000077 M0 M4 0.000175073684210526
BOK 0.824267508376797 0.000016 Healthy_CD34 Monocyte 0.0000411428571428571
BOK 0.906554149773801 0.000011 M2 Monocyte 0.0000297
BOK 0.872821289130368 0.000000044 M1 Monocyte 0.000000186352941176471
BOK 0.831233433810154 7.6e-11 M0 Monocyte 5.472e-10
BID 0.766713435917683 0.011 AML_CD34 M5 0.0163862068965517
BID 0.849565151102682 0.0194444444444444 M0 M5 0.00476220472440945
BID 0.749383640572565 0.00277777777777778 Healthy_CD34 M4 0.000771428571428571
BID 0.691159853840777 0.000012 Healthy_CD34 M5 0.000031609756097561
BID 0.806218675668972 0.0000037 M1 M4 0.0000114171428571429
BID 0.785469082912321 0.000000011 M2 M4 0.0000000495
BID 0.743579058669234 0.0000000036 M1 M5 0.0000000185142857142857
BID 0.660580953438376 2.6e-10 M3 M4 0.00000000165176470588235
BID 0.242636393352739 1.1e-10 Healthy_CD34 Monocyte 7.425e-10
BID 0.724441617283424 5.1e-11 M2 M5 3.79862068965517e-10
BID 0.269159995032075 3.6e-12 AML_CD34 Monocyte 3.1104e-11
BID 0.609256741820024 1.6e-12 M3 M5 1.50260869565217e-11
BID 0.298245656249035 9.5e-18 M0 Monocyte 2.28e-16
BID 0.213883745763837 5.4e-22 M3 Monocyte 2.916e-20
BID 0.261038513689036 1.1e-25 M1 Monocyte 1.188e-23
BID 0.254320184014578 1.1e-29 M2 Monocyte 2.376e-27
BCL2L2 0.886162909880358 0.049 Healthy_CD34 Monocyte 0.0653333333333333
BCL2L2 1.09000899861673 0.043 AML_CD34 M4 0.0576894409937888





BCL2L2 1.13966520249199 0.0381944444444444 AML_CD34 M5 0.00867153284671533
BCL2L2 1.10814871470204 0.0368055555555556 M3 M5 0.00848
BCL2L2 1.09824948356787 0.0319444444444444 M2 M5 0.00741492537313433
BCL2L2 0.915831208869128 0.0180555555555556 M0 M5 0.0044928
BCL2L2 1.13793124252447 0.00625 M1 M5 0.00163361344537815
BCL2L2 0.875927646732203 0.000027 M0 M4 0.0000655280898876404
BCL2L2 0.837245298706436 0.0000056 M0 Monocyte 0.0000165698630136986
BCL2L11 0.817514995100885 0.027 Healthy_CD34 M5 0.0369113924050633
BCL2L11 0.848369350164473 0.026 M3 M4 0.0357707006369427
BCL2L11 0.804971212282638 0.011 AML_CD34 M5 0.0163862068965517
BCL2L11 0.754850754422285 0.0256944444444444 Healthy_CD34 M4 0.0061953488372093
BCL2L11 0.840374526023186 0.00056 M2 M4 0.00104275862068966
BCL2L11 0.743268478891676 0.00038 AML_CD34 M4 0.00073945945945946
BCL2L11 0.779030915984434 0.000097 M3 Monocyte 0.000213795918367347
BCL2L11 0.693155728144975 0.00009 Healthy_CD34 Monocyte 0.0002025
BCL2L11 0.815980634372373 0.000039 M1 M5 0.0000915652173913043
BCL2L11 0.682520088474534 0.0000056 AML_CD34 Monocyte 0.0000165698630136986
BCL2L11 0.771689520196486 0.0000012 M2 Monocyte 0.00000418064516129032
BCL2L11 0.761794880178923 0.00000027 M0 M5 0.00000106036363636364
BCL2L11 0.753434005664875 0.0000000046 M1 M4 0.000000023106976744186
BCL2L11 0.691854772279476 1.3e-10 M1 Monocyte 8.50909090909091e-10
BCL2L11 0.703401703288796 1.1e-10 M0 M4 7.425e-10
BCL2L11 0.645911681170291 4.8e-11 M0 Monocyte 3.70285714285714e-10
BCL2L1 1.23514116549936 0.0291666666666667 Healthy_CD34 Monocyte 0.00692519083969466
BCL2L1 1.07811377589905 0.00037 M3 M4 0.000726545454545455
BCL2L1 1.18023580503551 0.00035 M1 M4 0:07
BCL2L1 1.28825483079069 0.000025 M1 M5 0.0000613636363636364
BCL2L1 1.17678626086264 0.0000015 M3 M5 0.00000498461538461539
BCL2L1 1.45527999378235 0.0000000077 M1 Monocyte 0.00000003696
BCL2L1 1.32935927074322 0.0000000019 M3 Monocyte 0.0000000110918918918919
BCL2L1 1.35500909914626 3.3e-12 M2 M4 2.97e-11
BCL2L1 1.47902394614099 4.2e-14 M2 M5 4.77473684210526e-13
BCL2L1 1.67078275796019 2.9e-17 M2 Monocyte 5.69454545454545e-16
BCL2A1 0.603205655280486 0.016 M0 M5 0.0227368421052632
BCL2A1 0.596707068712228 0.0375 M0 M4 0.00857647058823529
BCL2A1 0.345547528073482 0.0166666666666667 Healthy_CD34 M5 0.00418064516129032
BCL2A1 0.341824800169698 0.00042 Healthy_CD34 M4 0.00080283185840708
BCL2A1 0.28172567820071 0.000022 AML_CD34 M5 0.0000546206896551724
BCL2A1 0.278690529752977 0.0000016 AML_CD34 M4 0.00000523636363636364
BCL2A1 0.374678752531045 0.00000077 M1 M5 0.000002772
BCL2A1 0.370642181773966 0.0000000022 M1 M4 0.0000000125052631578947
BCL2A1 0.0799863363728203 5.7e-10 Healthy_CD34 Monocyte 0.00000000342
BCL2A1 0.168637817917145 9.4e-13 M3 M5 9.66857142857143e-12
BCL2A1 0.0652130402641195 2.4e-13 AML_CD34 Monocyte 2.592e-12
BCL2A1 0.237973171726627 6.1e-15 M2 Monocyte 7.75058823529412e-14
BCL2A1 0.139628289961294 6.8e-16 M0 Monocyte 9.792e-15
BCL2A1 0.166821012240966 1.4e-16 M3 M4 2.32615384615385e-15
BCL2A1 0.0390357914128408 8.1e-22 M3 Monocyte 3.4992e-20
BCL2A1 0.0867295474483146 1.6e-22 M1 Monocyte 1.152e-20
BCL2 1.10852854722758 0.011 M0 M4 0.0163862068965517
BCL2 1.12965016010982 0.0451388888888889 M2 Monocyte 0.0101007194244604
BCL2 1.14320921051288 0.0298611111111111 M0 M5 0.00703636363636364
BCL2 1.24274535135676 0.00037 AML_CD34 M4 0.000726545454545455
BCL2 1.25330124292858 0.00138888888888889 M0 Monocyte 0.000419417475728155
BCL2 1.28162502945577 0.00014 AML_CD34 M5 0.000296470588235294
BCL2 1.40504662454973 0.000051 AML_CD34 Monocyte 0.000118451612903226
BCL2 1.21015862067505 0.0000032 M1 M5 0.0000101647058823529
BCL2 1.25163755775748 0.000002 M3 M5 0.00000644776119402985
BCL2 1.17344696434873 0.0000013 M1 M4 0.00000445714285714286
BCL2 1.21366758664751 0.00000047 M3 M4 0.00000175034482758621
BCL2 1.32669793899957 0.000000034 M1 Monocyte 0.00000014688
BCL2 1.37217133347778 0.000000012 M3 Monocyte 0.0000000528979591836735
BBC3 1.08735067843387 0.036 M2 M5 0.0489056603773585
BBC3 1.1364551357906 0.016 M3 M4 0.0227368421052632
BBC3 0.851102061291693 0.0270833333333333 M0 M5 0.00648




BBC3 1.2424010332266 0.00022 M3 M5 0.000448301886792453
BBC3 1.42318522051382 0.000019 AML_CD34 M4 0.0000482823529411765
BBC3 0.778524230718742 0.0000075 M0 M4 0.000021888
BBC3 1.55586149664336 0.00000091 AML_CD34 M5 0.00000322229508196721
BBC3 0.650752849876492 0.00000069 M3 Monocyte 0.00000252610169491525
BBC3 0.526027081239692 0.0000004 Healthy_CD34 Monocyte 0.00000151578947368421
BBC3 0.56953957207223 1.6e-15 M2 Monocyte 2.16e-14
BBC3 0.4457957431691110.0000000000000000006 M0 Monocyte 1.85142857142857e-17
BBC3 0.4872650211366120.0000000000000000002 M1 Monocyte 7.2e-18
BAX 0.823110029233584 0.022 M0 Monocyte 0.0308571428571429
BAX 0.835050751146335 0.016 M0 M5 0.0227368421052632
BAX 0.83847187377086 0.0458333333333333 M3 M4 0.0101828571428571
BAX 0.862473143881513 0.0118055555555556 M2 M4 0.00300983606557377
BAX 0.635242232867981 0.00049 Healthy_CD34 M4 0.000920347826086957
BAX 0.774814742671967 0.00045 M1 Monocyte 0.000852631578947368
BAX 0.786054852800087 0.00013 M1 M5 0.000278019801980198
BAX 0.712807237267295 0.000039 M3 Monocyte 0.0000915652173913043
BAX 0.540036315076058 0.000034 Healthy_CD34 Monocyte 0.0000816
BAX 0.547870533141794 0.00002 Healthy_CD34 M5 0.0000502325581395349
BAX 0.723147814705684 0.0000095 M3 M5 0.0000263076923076923
BAX 0.733211355251049 0.0000056 M2 Monocyte 0.0000165698630136986
BAX 0.743847931875533 0.00000032 M2 M5 0.00000123428571428571
B2M 1.05933244069107 0.013 M0 M5 0.0191020408163265
B2M 0.791942053967213 0.0465277777777778 AML_CD34 Monocyte 0.010263829787234
B2M 0.878561612689705 0.01875 Healthy_CD34 M5 0.00462857142857143
B2M 0.940042948213445 0.0104166666666667 M2 M5 0.00267768595041322
B2M 0.907336981677027 0.00069 M1 M5 0.00127384615384615
B2M 0.902768665865441 0.00022 M0 Monocyte 0.000448301886792453
B2M 1.10616742128612 0.000016 M0 M4 0.0000411428571428571
B2M 0.858784204432078 0.000000096 M3 Monocyte 0.000000398769230769231
B2M 0.748714817466613 0.0000000097 Healthy_CD34 Monocyte 0.0000000455478260869565
B2M 0.773237337945192 7.1e-17 M1 Monocyte 1.278e-15
B2M 0.801109534284861 1.4e-18 M2 Monocyte 3.78e-17
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c. TCGA AML statistics genetics
gene Fold	Change P-Value GroupA GroupB adj.	P-Value
MCL1 0.612859626142771 0.047 M4_RUNX1 M4_RUNX1_not 0.361725
JAK2 0.761148575989693 0.036 M2_FLT3 M2_FLT3_not 0.361725
JAK2 0.794749503608146 0.036 M1_NPM1 M1_NPM1_not 0.361725
JAK2 0.614777539697286 0,07 M4_FLT3 M4_FLT3_not 0.248181818181818
JAK2 1.79764869623807 0,03 M0_RUNX1 M0_RUNX1_not 1,1
BID 0.796901173779609 0.038 M3_FLT3 M3_FLT3_not 0.361725
BID 1.29841650735952 0.044 M5_NPM1 M5_NPM1_not 0.361725
BID 1.37888295459029 0.032 M5_Normal_Karyotype M5_Normal_Karyotype_not 0.361725
BID 0.77017062307226 0,00 M4_CBFB_MYH11 M4_CBFB_MYH11_not 0.248181818181818
BID 1.42741802412088 0.0000035 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.0003185
BID 1.48735375973883 0.0000021 M4_NPM1 M4_NPM1_not 0.00028665
BCL2L2 1.35997650794728 0.00052 M1_NPM1 M1_NPM1_not 0.028392
BCL2L11 0.447384827550487 0.049 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.361725
BCL2L11 0.574565334213617 0.045 M4_RUNX1 M4_RUNX1_not 0.361725
BCL2L1 0.50518820365958 0.00000059 M4_CBFB_MYH11 M4_CBFB_MYH11_not 0.00016107
BCL2A1 0.524821962664371 0.049 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.361725
BCL2A1 9.17791640704799 0.024 M5_Normal_Karyotype M5_Normal_Karyotype_not 0.361725
BCL2A1 2.23617761433255 0.031 M4_NPM1 M4_NPM1_not 0.361725
BCL2 0.517243912716571 0.041 M5_Normal_Karyotype M5_Normal_Karyotype_not 0.361725
BCL2 1.78971339359243 0.039 M4_RUNX1 M4_RUNX1_not 0.361725
BCL2 0.669238387241732 0.014 M4_Normal_Karyotype M4_Normal_Karyotype_not 0,2
BCL2 0.56972559673218 0.00091 M4_NPM1 M4_NPM1_not 0.041405
BCL2 0.449887221345994 0.00039 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.0266175
BBC3 1.62075304760719 0,00 M2_NPM1 M2_NPM1_not 0.361725
BBC3 0.60069607522619 0.047 M4_RUNX1 M4_RUNX1_not 0.361725
BBC3 0.437927810847697 0,05 M2_CEBPA M2_CEBPA_not 0.203233333333333
BAX 1.37645223345365 0.023 M4_FLT3 M4_FLT3_not 0.361725
BAX 1.30017034863702 0.037 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.361725
BAX 1.40607959152019 0.016 M4_NPM1 M4_NPM1_not 0,2
BAX 1.45011434698119 0,02 M2_FLT3 M2_FLT3_not 0,6
BAK1 1.22853967071203 0.048 M1_CEBPA M1_CEBPA_not 0.361725
BAK1 0.742482316638929 0.037 M4_RUNX1 M4_RUNX1_not 0.361725
BAK1 0.752623373705534 0.018 M5_Normal_Karyotype M5_Normal_Karyotype_not 2,3
B2M 0.723942465080778 0.035 M1_FLT3 M1_FLT3_not 0.361725
B2M 0.648215513896212 0.013 M3_FLT3 M3_FLT3_not 0,2
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d. Hemap AML statistics genetics
gene Fold	Change P-Value GroupA GroupB adj. P-Value
MCL1 1.44828834340019 0:02 M2_FLT3 M2_FLT3_not 0.122553191489362
MCL1 0.506196272152554 0.016 M4_PML_RARA M4_PML_RARA_not 0.109714285714286
MCL1 1.67423830095391 0.00016 M4_CBFB_MYH11 M4_CBFB_MYH11_not 0.00354461538461538
MCL1 0.641295343172434 0.000026 M4_MLL M4_MLL_not 0.000832
JAK2 1.62828224077646 0.035 M5_FLT3 M5_FLT3_not 0.173793103448276
JAK2 1.34124551293129 0.032 M4_NPM1 M4_NPM1_not 0.170666666666667
JAK2 0.60181344561868 0.056944444 M4_PML_RARA M4_PML_RARA_not 0.0674742857142857
JAK2 1.50848114661595 0:11 M4_CBFB_MYH11 M4_CBFB_MYH11_not 0.0916666666666667
JAK2 0.733286346483175 0.00000048 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.00004608
JAK2 0.561175056102604 5.4e-10 M4_MLL M4_MLL_not 0.00000007776
BOK 1.05252173387062 0.047 M4_MLL M4_MLL_not 0.197485714285714
BOK 1.09243333969954 0.034 M2_FLT3 M2_FLT3_not 0.171789473684211
BOK 1.08912325130482 0.04722222 M1_NPM1 M1_NPM1_not 0.0593454545454545
BOK 1.13890182509818 0.0000058 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.000238628571428571
BID 1.17927062363548 0.033 M1_FLT3 M1_FLT3_not 0.171789473684211
BID 0.861824762058086 0.031 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.168452830188679
BID 1.17370261014633 0.023 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.127384615384615
BID 1.38415191748071 0.05625 M4_NPM1 M4_NPM1_not 0.0674742857142857
BID 1.29372407439415 0:15 M4_MLL M4_MLL_not 0.01728
BID 1.22964368155286 0:11 M1_Normal_Karyotype M1_Normal_Karyotype_not 0.0916666666666667
BID 0.387532618002298 0.00032 M4_PML_RARA M4_PML_RARA_not 0.00542117647058824
BID 1.30726034160321 0.00000074 M2_Normal_Karyotype M2_Normal_Karyotype_not 0.00005328
BCL2L2 1.12618045156325 0.006 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.055741935483871
BCL2L2 1.14476868253821 0.00031 M2_Normal_Karyotype M2_Normal_Karyotype_not 0.00542117647058824
BCL2L2 1.24396484490867 0.00015 M1_Normal_Karyotype M1_Normal_Karyotype_not 0.00354461538461538
BCL2L11 1.13465097088763 0.043 M4_MLL M4_MLL_not 0.194953846153846
BCL2L11 0.708712610261583 0.034 M4_PML_RARA M4_PML_RARA_not 0.171789473684211
BCL2L11 0.689433444956833 0.021 M4_Complex_Karyotype M4_Complex_Karyotype_not 0.0875
BCL2L11 1.11317224078842 0.016 M1_Normal_Karyotype M1_Normal_Karyotype_not 0.109714285714286
BCL2L11 1.2213135078751 0.00024 M2_Normal_Karyotype M2_Normal_Karyotype_not 0.004608
BCL2L1 1.19547815172798 0.043 M0_FLT3 M0_FLT3_not 0.194953846153846
BCL2L1 0.781148122411102 0.039 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 1.Mar
BCL2L1 0.742261182267481 0.022 M1_FLT3 M1_FLT3_not 0.12672
BCL2L1 2.53961519518251 0.0680555555 M4_PML_RARA M4_PML_RARA_not 0.0742736842105263
BCL2L1 0.710124862023932 0:29 M1_NPM1 M1_NPM1_not 0.0309333333333333
BCL2L1 0.59791219049376 0:29 M0_RUNX1 M0_RUNX1_not 0.0309333333333333
BCL2L1 0.662600782521901 0.00002 M4_CBFB_MYH11 M4_CBFB_MYH11_not 0.00072
BCL2A1 1.55750398222968 0.048 M1_Normal_Karyotype M1_Normal_Karyotype_not 0.197485714285714
BCL2A1 1.65920964456813 0.022 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.12672
BCL2A1 2.22686664880868 0.017 M4_NPM1 M4_NPM1_not 0.113860465116279
BCL2A1 1.58642657574795 0.06597222 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.0739459459459459
BCL2A1 0.151745146078337 0.00054 M4_PML_RARA M4_PML_RARA_not 0.00864
BCL2 0.733797221400413 0.048 M5_NPM1 M5_NPM1_not 0.197485714285714
BCL2 0.860405437834124 0.045 M1_FLT3 M1_FLT3_not 0.196363636363636
BCL2 1.28119581653159 0.044 M3_PML_RARA M3_PML_RARA_not 0.194953846153846
BCL2 0.852592588798731 0.018 M3_FLT3 M3_FLT3_not 0.8
BCL2 0.67451524953953 0.013 M5_FLT3 M5_FLT3_not 0.65
BCL2 0.82269339973893 0:42 M4_NPM1 M4_NPM1_not 0.0417103448275862
BCL2 0.850232600007102 0.00021 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.00432
BCL2 0.751107654233825 0.000052 M5_Normal_Karyotype M5_Normal_Karyotype_not 0.0014976
BCL2 1.29859627544566 0.0000049 M4_MLL M4_MLL_not 0.0002352
BCL2 0.838851404076079 0.0000026 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.00014976
BBC3 0.798200609781568 0.046 M3_FLT3 M3_FLT3_not 0.197485714285714
BBC3 0.784040934259313 0.044 M5_NPM1 M5_NPM1_not 0.194953846153846
BBC3 0.831310526735062 0.06527777 M1_FLT3 M1_FLT3_not 0.0739459459459459
BBC3 0.811121389993591 0.047222222 M1_NPM1 M1_NPM1_not 0.0593454545454545
BBC3 0.778278216529712 0.005 M4_CBFB_MYH11 M4_CBFB_MYH11_not 0.048
BBC3 1.23589818369627 0.00064 M2_RUNX1_RUNX1T1 M2_RUNX1_RUNX1T1_not 0.00936
BBC3 1.72833190839971 5.9e-13 M4_MLL M4_MLL_not 1.6992e-10
BAX 0.778002319049533 0:04 M0_Complex_Karyotype M0_Complex_Karyotype_not 0.188852459016393
BAX 1.57665571078159 0.012 M2_FLT3 M2_FLT3_not 0.0886153846153846
BAX 1.28313987970808 0:39 M1_NPM1 M1_NPM1_not 0.0401142857142857
BAX 1.52310439266921 0:11 M3_FLT3 M3_FLT3_not 0.0916666666666667
BAX 1.37826360031991 0.00089 M1_FLT3 M1_FLT3_not 0.0122057142857143
BAX 1.57243937736906 0.00008 M4_NPM1 M4_NPM1_not 0.00209454545454545
B2M 1.08817349938241 0.037 M4_NPM1 M4_NPM1_not 0.180610169491525
B2M 0.794876633296565 0.023 M4_PML_RARA M4_PML_RARA_not 0.127384615384615
B2M 0.936691458305754 0:02 M4_MLL M4_MLL_not 0.122553191489362
B2M 1.25873564626617 0.018 M1_Complex_Karyotype M1_Complex_Karyotype_not 0.8
B2M 1.10562717059934 0.00065 M4_Normal_Karyotype M4_Normal_Karyotype_not 0.00936
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Table S6: GSEA pathway analysis results comparing FAB M4-M5 and M0-M1








Phenotypes compared: FAB M4 and M5 vs. M0 and M1
FDR cutoff 0.1 used for filtering in both Hemap and TCGA data sets
Tabs 1-2 contain GSEA results upregulated in M4 and M5 groups, compared to 
M0 and M1 groups. Pathway FDR and NES values shown in Figure 4C are 
highlighted for Hemap GSEA results (a: Hemap_pathways_M4_M5). 
Similar/Same pathways are highlighted for TCGA AML data set (b: 
TCGA_pathways_FAB_M4_M5). c-d contain GSEA results upregulated in M0 
and M1 groups, compared to M4 and M5 groups.
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a. Hemap pathways M4 M5
NAME SIZE NES NOM p-val FDR q-val FWER p-val
LYSOSOME-KEGG_MSIGDB_C2 115 2.3478072 0.0 0.0 0.0
COMPLEMENT-MSIGDB_HALLMARKS 195 2.343244 0.0 0.0 0.0
INFLAMMATORY_RESPONSE-MSIGDB_HALLMARKS 198 2.3351223 0.0 0.0 0.0
TNFA_SIGNALING_VIA_NFKB-MSIGDB_HALLMARKS 198 2.3276932 0.0 0.0 0.0
AUTOPHAGY_PERERA 126 2.3188524 0.0 0.0 0.0
INNATE_IMMUNE_SYSTEM-REACTOME_MSIGDB_C2 228 2.250565 0.0 0.0 0.0
INTERFERON_GAMMA_RESPONSE-MSIGDB_HALLMARKS 192 2.1368678 0.0 1.7228287E-4 0.001
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES-REACTOME_MSIGDB_C2 47 2.1088302 0.0 3.0182963E-4 0.002
LEISHMANIA_INFECTION-KEGG_MSIGDB_C2 62 2.08367 0.0 5.348594E-4 0.004
TOLL_RECEPTOR_CASCADES-REACTOME_MSIGDB_C2 109 2.0506792 0.0 4.8137348E-4 0.004
PEPTIDE_GPCRS_HOMO_SAPIENS-WIKIPW 74 2.043489 0.0 7.6871586E-4 0.007
REGULATION_OF_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY_HOMO_SAPIENS-WIKIPW 132 2.0370507 0.0 8.063938E-4 0.008
GRAFT_VERSUS_HOST_DISEASE-KEGG_MSIGDB_C2 34 2.0347688 0.0 7.443635E-4 0.008
ASTHMA-KEGG_MSIGDB_C2 26 2.0329287 0.0 6.911947E-4 0.008
COMPLEMENT_CASCADE-REACTOME_MSIGDB_C2 27 2.026121 0.0 8.8256015E-4 0.011
GLYCOSPHINGOLIPID_METABOLISM-REACTOME_MSIGDB_C2 31 2.0222964 0.0 8.2740013E-4 0.011
DEFENSINS-REACTOME_MSIGDB_C2 20 2.0215194 0.0 7.787295E-4 0.011
LATENT_INFECTION_OF_HOMO_SAPIENS_WITH_MYCOBACTERIUM_TUBERCULOSIS-REACTOME_MSIGDB_C231 2.0187643 0.0 8.029891E-4 0.012
IL6_JAK_STAT3_SIGNALING-MSIGDB_HALLMARKS 84 2.0077882 0.0 8.237802E-4 0.013
TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY_HOMO_SAPIENS-WIKIPW 94 1.9875175 0.0 0.0013735475 0.023
COAGULATION-MSIGDB_HALLMARKS 135 1.9844366 0.0 0.0013637216 0.024
ALLOGRAFT_REJECTION-MSIGDB_HALLMARKS 196 1.9836742 0.0 0.0013569181 0.025
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION-KEGG_MSIGDB_C2 241 1.9803885 0.0 0.0014005655 0.026
NOD_PATHWAY_HOMO_SAPIENS-WIKIPW 39 1.9762907 0.0 0.0014428999 0.028
TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY-KEGG_MSIGDB_C2 93 1.9625736 0.0 0.001962531 0:04
ALLOGRAFT_REJECTION-KEGG_MSIGDB_C2 33 1.9615821 0.0 0.0019347536 0.041
TYPE_I_DIABETES_MELLITUS-KEGG_MSIGDB_C2 38 1.9583794 0.0 0.0019937467 0.044
ENDOGENOUS_TLR_SIGNALING-NCI_NATURE_V4_PID 21 1.9443305 0.0 0.0029056724 0.064
NKT_PATHWAY-BIOCARTA_MSIGDB_C2 28 1.9425817 0.0 0.0028884178 0.066
AUTOIMMUNE_THYROID_DISEASE-KEGG_MSIGDB_C2 43 1.9289705 0.0016891892 0.0034312068 0.082
INITIAL_TRIGGERING_OF_COMPLEMENT-REACTOME_MSIGDB_C2 12 1.9231982 0.0 0.0037407903 0.092
TYPE_II_INTERFERON_SIGNALING_IFNG_HOMO_SAPIENS-WIKIPW 45 1.9084904 0.001858736 0.0049311225 0,086111111
UROKINASE_TYPE_PLASMINOGEN_ACTIVATOR_UPA_AND_UPAR_MEDIATED_SIGNALING-NCI_NATURE_V4_PID41 1.9069377 0.0 0.0048520663 0,0875
INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION-KEGG_MSIGDB_C2 43 1.8958616 0.0 0.0055542206 0,102083333
G_ALPHA_I_SIGNALLING_EVENTS-REACTOME_MSIGDB_C2 178 1.8942508 0.0 0.0056667486 0,106944444
INTERFERON_GAMMA_SIGNALING-REACTOME_MSIGDB_C2 54 1.8881397 0.0 0.006112306 0:17
MIR_TARGETED_GENES_IN_LEUKOCYTES_TARBASE_HOMO_SAPIENS-WIKIPW 124 1.8868557 0.0 0.0060744053 0,120138889
NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY-KEGG_MSIGDB_C2 59 1.8848151 0.0 0.0061962404 0,124305556
DRUG_METABOLISM_OTHER_ENZYMES-KEGG_MSIGDB_C2 36 1.8839298 0.0 0.006161087 0,126388889
TRYPTOPHAN_METABOLISM-KEGG_MSIGDB_C2 39 1.8723725 0.0 0.0072437017 0,147222222
XENOBIOTIC_METABOLISM-MSIGDB_HALLMARKS 198 1.8710536 0.0 0.007181866 0,149305556
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2-REACTOME_MSIGDB_C2 78 1.8676574 0.0 0.0073516537 0,154861111
SPHINGOLIPID_METABOLISM-REACTOME_MSIGDB_C2 60 1.8656232 0.0 0.0073786466 0,158333333
AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM-KEGG_MSIGDB_C2 44 1.8603723 0.0 0.007975923 0:25
CLASS_A1_RHODOPSIN_LIKE_RECEPTORS-REACTOME_MSIGDB_C2 266 1.8585489 0.0 0.008198349 0:26
BLYMPHOCYTE_PATHWAY-BIOCARTA_MSIGDB_C2 11 1.8583672 0.0 0.008020124 0:26
COMP_PATHWAY-BIOCARTA_MSIGDB_C2 17 1.8539504 0.0037453184 0.008232725 0:27
MHC_CLASS_II_ANTIGEN_PRESENTATION-REACTOME_MSIGDB_C2 85 1.8520563 0.0 0.008308948 0,193055556
ASBCELL_PATHWAY-BIOCARTA_MSIGDB_C2 12 1.8385426 0.0038535646 0.010367282 0,233333333
BETA_DEFENSINS-REACTOME_MSIGDB_C2 15 1.8373345 0.0 0.010327304 0,235416667
GRANULOCYTES_PATHWAY-BIOCARTA_MSIGDB_C2 13 1.8350328 0.0 0.010567534 0:35
PEPTIDE_LIGAND_BINDING_RECEPTORS-REACTOME_MSIGDB_C2 163 1.8329688 0.0 0.010687501 0,249305556
BETA2_INTEGRIN_CELL_SURFACE_INTERACTIONS-NCI_NATURE_V4_PID 28 1.8259956 0.0 0.011866686 0,277083333
COMPLEMENT_AND_COAGULATION_CASCADES_HOMO_SAPIENS-WIKIPW 59 1.8206196 0.0 0.012974642 0,303472222
GLYCOSAMINOGLYCAN_DEGRADATION-KEGG_MSIGDB_C2 20 1.8106389 0.0018518518 0.015000159 0,340972222
VIRAL_MYOCARDITIS-KEGG_MSIGDB_C2 66 1.8059531 0.0 0.016268117 0,370138889
ANTIGEN_PROCESSING_AND_PRESENTATION-KEGG_MSIGDB_C2 69 1.8056929 0.0017271157 0.016046226 0,370833333
REGULATION_OF_COMPLEMENT_CASCADE-REACTOME_MSIGDB_C2 11 1.7962474 0.0 0.018429259 0,406944444
OTHER_GLYCAN_DEGRADATION-KEGG_MSIGDB_C2 14 1.7960724 0.0038910506 0.018177697 0,407638889
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL-REACTOME_MSIGDB_C257 1.7958027 0.0033898305 0.01805409 0,408333333
CELLULAR_ROLES_OF_ANTHRAX_TOXIN-NCI_NATURE_V4_PID 20 1.7946202 0.0019193857 0.018011529 0,411111111
ACTIVATED_TLR4_SIGNALLING-REACTOME_MSIGDB_C2 87 1.77979 0.0 0.022874016 0,466666667
AMB2_INTEGRIN_SIGNALING-NCI_NATURE_V4_PID 39 1.7786366 0.0 0.023003928 0,470833333
COMPLEMENT_ACTIVATION_CLASSICAL_PATHWAY_HOMO_SAPIENS-WIKIPW 15 1.7775025 0.0018691589 0.02295853 0,475694444
IL1_AND_MEGAKARYOTYCES_IN_OBESITY_HOMO_SAPIENS-WIKIPW 24 1.7713904 0.0 0.02480294 0,502777778
COMPLEMENT_AND_COAGULATION_CASCADES-KEGG_MSIGDB_C2 67 1.7684401 0.0 0.025404943 0,511805556
FRUCTOSE_AND_MANNOSE_METABOLISM-KEGG_MSIGDB_C2 33 1.76629 0.001858736 0.025670573 0,518055556
SELENIUM_MICRONUTRIENT_NETWORK_HOMO_SAPIENS-WIKIPW 75 1.7659597 0.0 0.025451915 0,520138889
VITAMIN_A_AND_CAROTENOID_METABOLISM_HOMO_SAPIENS-WIKIPW 41 1.7642174 0.0034843206 0.025775777 0,525694444
MIR_TARGETED_GENES_IN_ADIPOCYTES_TARBASE_HOMO_SAPIENS-WIKIPW 18 1.7541918 0.008710802 0.029044293 0,554166667
PROSTAGLANDIN_SYNTHESIS_AND_REGULATION_HOMO_SAPIENS-WIKIPW 30 1.7526916 0.0 0.029093375 0,556944444
PATHOGENIC_ESCHERICHIA_COLI_INFECTION_HOMO_SAPIENS-WIKIPW 48 1.7484798 0.0018552876 0.030593485 0,570833333
ESTROGEN_METABOLISM_HOMO_SAPIENS-WIKIPW 11 1.7388055 0.0 0.034731656 0,602083333
CHEMOKINE_SIGNALING_PATHWAY-KEGG_MSIGDB_C2 174 1.7384808 0.0 0.034390893 0,603472222
ALLOGRAFT_REJECTION_HOMO_SAPIENS-WIKIPW 75 1.7381173 0.0 0.0340606 0,603472222
CLASSIC_PATHWAY-BIOCARTA_MSIGDB_C2 12 1.7356001 0.0 0.03503313 0,6125
CHOLESTEROL_HOMEOSTASIS-MSIGDB_HALLMARKS 70 1.7279915 0.0 0.038405422 0,063194444
NFKB_PATHWAY-BIOCARTA_MSIGDB_C2 22 1.7265931 0.0074626864 0.03868125 0,639583333
INFLAMMASOMES-REACTOME_MSIGDB_C2 16 1.725987 0.0038461538 0.038419243 0,640972222
TRAFFICKING_AND_PROCESSING_OF_ENDOSOMAL_TLR-REACTOME_MSIGDB_C2 11 1.7243962 0.0036231885 0.038673766 0,642361111
GPCR_LIGAND_BINDING-REACTOME_MSIGDB_C2 363 1.7220628 0.0 0.039540596 0,647916667
NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS-REACTOME_MSIGDB_C243 1.7134289 0.0017513135 0.04361832 0,658333333
ACYL_CHAIN_REMODELLING_OF_PC-REACTOME_MSIGDB_C2 21 1.712849 0.001858736 0.043278914 0,658333333
NRF2_PATHWAY_HOMO_SAPIENS-WIKIPW 126 1.7114978 0.0 0.04350631 0,660416667
GALACTOSE_METABOLISM-KEGG_MSIGDB_C2 25 1.7110187 0.0018832391 0.043373715 0,661111111
IL5_PATHWAY-BIOCARTA_MSIGDB_C2 10 1.7108009 0.0076045627 0.042979483 0,661111111
TRANSPORT_OF_ORGANIC_ANIONS-REACTOME_MSIGDB_C2 11 1.7085909 0.0038314175 0.043693453 0,663194444
GLYCOLYSIS_GLUCONEOGENESIS-KEGG_MSIGDB_C2 58 1.7075341 0.0 0.043797065 0,664583333
NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY-KEGG_MSIGDB_C2 120 1.706334 0.0 0.04397289 0,066666667
ALPHA9_BETA1_INTEGRIN_SIGNALING_EVENTS-NCI_NATURE_V4_PID 23 1.7053128 0.010928961 0.0440723 0,668055556
LAIR_PATHWAY-BIOCARTA_MSIGDB_C2 15 1.7032646 0.0057471264 0.04469221 0,669444444
PENTOSE_PHOSPHATE_PATHWAY-KEGG_MSIGDB_C2 26 1.700436 0.0072202166 0.045846205 0,675694444
PORPHYRIN_AND_CHLOROPHYLL_METABOLISM-KEGG_MSIGDB_C2 27 1.69813 0.005291005 0.046777774 0,678472222
EPITHELIAL_MESENCHYMAL_TRANSITION-MSIGDB_HALLMARKS 195 1.6976151 0.0 0.046637498 0,679861111
MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE-REACTOME_MSIGDB_C2 78 1.6952728 0.0 0.04758159 0,68125
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APOPTOSIS-MSIGDB_HALLMARKS 154 1.6921626 0.0 0.049193498 0,684722222
PATHOGENIC_ESCHERICHIA_COLI_INFECTION-KEGG_MSIGDB_C2 47 1.6890907 0.0034965035 0.050781187 0,685416667
PROTEOLYTIC_CLEAVAGE_OF_SNARE_COMPLEX_PROTEINS-REACTOME_MSIGDB_C2 16 1.6857909 0.007633588 0.052279808 0,686805556
PHOSPHOLIPID_METABOLISM-REACTOME_MSIGDB_C2 184 1.6856605 0.0 0.051788203 0,686805556
CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL-REACTOME_MSIGDB_C2 83 1.6852442 0.0 0.05151062 0,06875
OXIDATIVE_STRESS_HOMO_SAPIENS-WIKIPW 27 1.6797848 0.007707129 0.054458633 0,689583333
CCR5_PATHWAY-BIOCARTA_MSIGDB_C2 16 1.6789361 0.011049724 0.05451289 0,690972222
AFLATOXIN_B1_METABOLISM_HOMO_SAPIENS-WIKIPW 7 1.6753579 0.0039138943 0.056466527 0,692361111
IL10_PATHWAY-BIOCARTA_MSIGDB_C2 17 1.6735388 0.013513514 0.05728159 0,693055556
IL8_AND_CXCR2_MEDIATED_SIGNALING_EVENTS-NCI_NATURE_V4_PID 33 1.6728045 0.006968641 0.05733942 0,693055556
TCA_CYCLE_HOMO_SAPIENS-WIKIPW 15 1.66867 0.014897579 0.0598627 0,69375
HYPOXIA-MSIGDB_HALLMARKS 196 1.668391 0.0 0.059540678 0,69375
TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION-REACTOME_MSIGDB_C271 1.6667705 0.0017123288 0.05997225 1.0
GLYCOLYSIS-MSIGDB_HALLMARKS 197 1.6655061 0.0 0.060486093 1.0
INSULIN_RECEPTOR_RECYCLING-REACTOME_MSIGDB_C2 23 1.6649512 0.009259259 0.06040619 1.0
CREATION_OF_C4_AND_C2_ACTIVATORS-REACTOME_MSIGDB_C2 8 1.6642468 0.018975332 0.0603052 1.0
EXTRACELLULAR_MATRIX_ORGANIZATION-REACTOME_MSIGDB_C2 83 1.6633364 0.0 0.060440727 1.0
METABOLISM_OF_CARBOHYDRATES-REACTOME_MSIGDB_C2 225 1.6589205 0.0 0.06327869 1.0
EICOSANOID_SYNTHESIS_HOMO_SAPIENS-WIKIPW 19 1.6586562 0.007968128 0.06296571 1.0
CITRIC_ACID_CYCLE_TCA_CYCLE-REACTOME_MSIGDB_C2 17 1.658191 0.0056179776 0.06284566 1.0
ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S-REACTOME_MSIGDB_C2 43 1.6561605 0.0051993066 0.063923225 1.0
PPAR_SIGNALING_PATHWAY-KEGG_MSIGDB_C2 65 1.6538312 0.001669449 0.06500077 1.0
CYTOKINES_AND_INFLAMMATORY_RESPONSE_HOMO_SAPIENS-WIKIPW 26 1.6532228 0.0036429872 0.06488565 1.0
HEMATOPOIETIC_CELL_LINEAGE-KEGG_MSIGDB_C2 80 1.6530755 0.0 0.06445038 1.0
GPCRS_CLASS_A_RHODOPSIN_LIKE_HOMO_SAPIENS-WIKIPW 239 1.6507281 0.0 0.06589687 1.0
IL6_MEDIATED_SIGNALING_EVENTS-NCI_NATURE_V4_PID 47 1.650253 0.008695652 0.065697476 1.0
TRANS_GOLGI_NETWORK_VESICLE_BUDDING-REACTOME_MSIGDB_C2 55 1.6474315 0.0017006802 0.067326166 1.0
INTEGRIN_CELL_SURFACE_INTERACTIONS-REACTOME_MSIGDB_C2 75 1.6473687 0.0 0.066837445 1.0
GLYCEROPHOSPHOLIPID_BIOSYNTHESIS-REACTOME_MSIGDB_C2 79 1.6460551 0.0 0.06735077 1.0
CITRATE_CYCLE_TCA_CYCLE-KEGG_MSIGDB_C2 28 1.6457946 0.007677543 0.067013696 1.0
PYRIMIDINE_CATABOLISM-REACTOME_MSIGDB_C2 11 1.6452745 0.011257036 0.06688107 1.0
ESTROGEN_RESPONSE_LATE-MSIGDB_HALLMARKS 194 1.6426522 0.0 0.068143494 1.0
FLUOROPYRIMIDINE_ACTIVITY_HOMO_SAPIENS-WIKIPW 30 1.6416718 0.005524862 0.06829588 1.0
SRCRPTP_PATHWAY-BIOCARTA_MSIGDB_C2 11 1.6410359 0.01178782 0.06828524 1.0
PASSIVE_TRANSPORT_BY_AQUAPORINS-REACTOME_MSIGDB_C2 11 1.6408049 0.01764706 0.067888156 1.0
TRYPTOPHAN_METABOLISM_HOMO_SAPIENS-WIKIPW 45 1.6398511 0.0035211267 0.067991175 1.0
ACYL_CHAIN_REMODELLING_OF_PI-REACTOME_MSIGDB_C2 14 1.6395913 0.01171875 0.067639105 1.0
SEMAPHORIN_INTERACTIONS_HOMO_SAPIENS-WIKIPW 59 1.6353679 0.012522361 0.07031885 1.0
IL1_SIGNALING-REACTOME_MSIGDB_C2 37 1.634831 0.006980803 0.07018751 1.0
CELL_ADHESION_MOLECULES_CAMS-KEGG_MSIGDB_C2 126 1.6340678 0.0016313214 0.07024489 1.0
ACYL_CHAIN_REMODELLING_OF_PE-REACTOME_MSIGDB_C2 20 1.6337074 0.016759777 0.069967195 1.0
STARCH_AND_SUCROSE_METABOLISM-KEGG_MSIGDB_C2 34 1.633455 0.008833922 0.06968275 1.0
HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM-REACTOME_MSIGDB_C2 49 1.6303673 0.00681431 0.0715993 1.0
THE_ACTIVATION_OF_ARYLSULFATASES-REACTOME_MSIGDB_C2 11 1.6280007 0.009416196 0.0728954 1.0
IL_13_PATHWAY-ST_MSIGDB_C2 7 1.6248584 0.021868788 0.07495972 1.0
ARYL_HYDROCARBON_RECEPTOR_PATHWAY_HOMO_SAPIENS-WIKIPW 40 1.624539 0.012048192 0.07474888 1.0
TRYPTOPHAN_CATABOLISM-REACTOME_MSIGDB_C2 11 1.6241167 0.019148936 0.07451774 1.0
FARNESOID_X_RECEPTOR_PATHWAY_HOMO_SAPIENS-WIKIPW 19 1.6227708 0.015296367 0.07507139 1.0
SIGNALING_BY_ILS-REACTOME_MSIGDB_C2 104 1.6220388 0.004862237 0.075114556 1.0
MMP_CYTOKINE_CONNECTION-SA_MSIGDB_C2 14 1.6217715 0.020295203 0.07485968 1.0
INTERLEUKIN_13_PATHWAY-ST_MSIGDB_C2 7 1.6205595 0.0058479533 0.07530522 1.0
SYNDECAN_1_MEDIATED_SIGNALING_EVENTS-NCI_NATURE_V4_PID 46 1.620366 0.010791367 0.074899785 1.0
TH1TH2_PATHWAY-BIOCARTA_MSIGDB_C2 19 1.6182076 0.017408123 0.07628678 1.0
PYRIMIDINE_METABOLISM-REACTOME_MSIGDB_C2 23 1.6152003 0.017889088 0.07797477 1.0
MTORC1_SIGNALING-MSIGDB_HALLMARKS 190 1.6146309 0.0 0.07799177 1.0
SYNTHESIS_SECRETION_AND_DEACYLATION_OF_GHRELIN-REACTOME_MSIGDB_C2 14 1.6144068 0.013487476 0.077609934 1.0
TOLL_PATHWAY-BIOCARTA_MSIGDB_C2 36 1.6143557 0.0055555557 0.077145904 1.0
ADIPOGENESIS_HOMO_SAPIENS-WIKIPW 131 1.6126872 0.0015923567 0.07807567 1.0
FOXM1_TRANSCRIPTION_FACTOR_NETWORK-NCI_NATURE_V4_PID 40 1.6104096 0.014545455 0.079284914 1.0
IRON_UPTAKE_AND_TRANSPORT-REACTOME_MSIGDB_C2 36 1.6093265 0.01056338 0.0795856 1.0
SEMAPHORIN_INTERACTIONS-REACTOME_MSIGDB_C2 61 1.607096 0.005226481 0.080940954 1.0
PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATION_AND_ARYLSULFATASE_ACTIVATION-REACTOME_MSIGDB_C225 1.6052597 0.02550091 0.08207442 1.0
EXTRINSIC_PATHWAY_FOR_APOPTOSIS-REACTOME_MSIGDB_C2 13 1.6046011 0.015779093 0.08203759 1.0
TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING-REACTOME_MSIGDB_C2 25 1.6044006 0.013409962 0.081723355 1.0
VITAMIN_D_METABOLISM_HOMO_SAPIENS-WIKIPW 10 1.603438 0,086805556 0.081995435 1.0
SIGNAL_REGULATORY_PROTEIN_SIRP_FAMILY_INTERACTIONS-REACTOME_MSIGDB_C2 12 1.6016104 0:01 0.083169356 1.0
FACILITATIVE_NA_INDEPENDENT_GLUCOSE_TRANSPORTERS-REACTOME_MSIGDB_C2 11 1.6015124 0.018691588 0.08272985 1.0
MEMBRANE_TRAFFICKING-REACTOME_MSIGDB_C2 119 1.5968033 0:16 0.086138286 1.0
ADIPOGENESIS-MSIGDB_HALLMARKS 192 1.5934712 0.0 0.08855022 1.0
SYSTEMIC_LUPUS_ERYTHEMATOSUS-KEGG_MSIGDB_C2 97 1.593325 0.0033112583 0.08819583 1.0
FATTY_ACID_METABOLISM-MSIGDB_HALLMARKS 151 1.5932225 0.0 0.08775134 1.0
IL2_STAT5_SIGNALING-MSIGDB_HALLMARKS 195 1.5931234 0.0014925373 0.08731164 1.0
PLATELET_SENSITIZATION_BY_LDL-REACTOME_MSIGDB_C2 16 1.5926871 0.032136105 0.08717848 1.0
RECYCLING_PATHWAY_OF_L1-REACTOME_MSIGDB_C2 26 1.5920074 0.018214935 0.08729935 1.0
VIBRIO_CHOLERAE_INFECTION-KEGG_MSIGDB_C2 54 1.5905054 0.008896797 0.08819444 1.0
CHYLOMICRON_MEDIATED_LIPID_TRANSPORT-REACTOME_MSIGDB_C2 15 1.5871545 0.026768642 0.0905402 1.0
METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS-REACTOME_MSIGDB_C2 451 1.5862147 0.0 0.09072347 1.0
LYSOSOME_VESICLE_BIOGENESIS-REACTOME_MSIGDB_C2 22 1.5859137 0.029357798 0.090469696 1.0
INSULIN_SIGNALING_PATHWAY-KEGG_MSIGDB_C2 136 1.5853269 0.0032626428 0.09035542 1.0
PRION_DISEASES-KEGG_MSIGDB_C2 35 4,101388889 0.017667845 0.09042277 1.0
INFLAMMATORY_RESPONSE_PATHWAY_HOMO_SAPIENS-WIKIPW 32 1.5844898 0.0120689655 0.090010196 1.0
P53_PATHWAY-MSIGDB_HALLMARKS 192 1.5824254 0.0 0.09131202 1.0
ENDOSOMAL_VACUOLAR_PATHWAY-REACTOME_MSIGDB_C2 8 1.5820465 0.018691588 0.09109514 1.0
PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE-REACTOME_MSIGDB_C2 37 1.5806319 0.014414415 0.09172881 1.0
ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC-REACTOME_MSIGDB_C220 1.5803474 0.020408163 0.091519676 1.0
CACAM_PATHWAY-BIOCARTA_MSIGDB_C2 13 1.5784625 0.020446097 0.09277978 1.0
GLUTATHIONE_METABOLISM-KEGG_MSIGDB_C2 41 1.5754027 0.012567325 0.09499628 1.0
TID_PATHWAY-BIOCARTA_MSIGDB_C2 18 1.5753582 0.017667845 0.0945289 1.0
CS_DS_DEGRADATION-REACTOME_MSIGDB_C2 12 1.5745596 0.022944551 0.09476724 1.0
IL1R_PATHWAY-BIOCARTA_MSIGDB_C2 33 1.5736711 0.015706806 0.095026664 1.0
REGULATION_OF_RAS_FAMILY_ACTIVATION-NCI_NATURE_V4_PID 32 1.5717614 0.0144665465 0.09619591 1.0
CA_DEPENDENT_EVENTS-REACTOME_MSIGDB_C2 29 1.5716568 0.01908397 0.095783725 1.0
VITAMIN_B12_METABOLISM_HOMO_SAPIENS-WIKIPW 47 1.5710026 0.003539823 0.09583495 1.0
MONOCYTE_PATHWAY-BIOCARTA_MSIGDB_C2 10 1.5693622 0.029350106 0.096923806 1.0
IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_RIP1-REACTOME_MSIGDB_C2 8 1.5678713 0.017892644 0.09768813 1.0
GLUCOSE_METABOLISM-REACTOME_MSIGDB_C2 62 1.5673448 0.010291595 0.097697824 1.0
























































































































































NAME SIZE NES NOM p-val
GENERIC_TRANSCRIPTION_PATHWAY-REACTOME_MSIGDB_C2 315 -2.3055868 0.0
MYC_TARGETS_V1-MSIGDB_HALLMARKS 178 -2.0839288 0.0
MRNA_PROCESSING_HOMO_SAPIENS-WIKIPW 121 -2.0505354 0.0
NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX-REACTOME_MSIGDB_C2 59 -2.0292943 0.0
RIBOSOME-KEGG_MSIGDB_C2 41 -2.01833 0.0
PEPTIDE_CHAIN_ELONGATION-REACTOME_MSIGDB_C2 39 -2.0020952 0.0
3_UTR_MEDIATED_TRANSLATIONAL_REGULATION-REACTOME_MSIGDB_C2 53 -1.9967451 0.0
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA-REACTOME_MSIGDB_C2 128 -1.9441764 0.0
MRNA_PROCESSING-REACTOME_MSIGDB_C2 146 -1.900145 0.0
CYTOPLASMIC_RIBOSOMAL_PROTEINS_HOMO_SAPIENS-WIKIPW 46 -1.8866994 0.0
MRNA_SPLICING-REACTOME_MSIGDB_C2 100 -1.8830794 0.0
MRNA_3_END_PROCESSING-REACTOME_MSIGDB_C2 32 -1.8646716 0.0
PACKAGING_OF_TELOMERE_ENDS-REACTOME_MSIGDB_C2 37 -1.8609581 0.0
TRANSCRIPTION-REACTOME_MSIGDB_C2 175 -1.8558459 0.0
FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX-REACTOME_MSIGDB_C2 26 -1.8296608 0.0
SIGNALING_BY_FGFR1_FUSION_MUTANTS-REACTOME_MSIGDB_C2 17 -1.8210053 0.0021413276
SIGNALING_BY_FGFR1_MUTANTS-REACTOME_MSIGDB_C2 28 -1.8160412 0.0
RNA_DEGRADATION-KEGG_MSIGDB_C2 56 -1.8040515 0.0
RNA_POL_I_PROMOTER_OPENING-REACTOME_MSIGDB_C2 42 -1.7719352 0.00456621
CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_TERMINATION_REGION-REACTOME_MSIGDB_C2 40 -1.7631412 0.0023696683
SPLICEOSOME-KEGG_MSIGDB_C2 119 -1.7603718 0.0
METABOLISM_OF_NON_CODING_RNA-REACTOME_MSIGDB_C2 44 -1.7573915 0.0046620048
TELOMERE_MAINTENANCE-REACTOME_MSIGDB_C2 63 -1.7571934 0.0
TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM-REACTOME_MSIGDB_C2 51 -1.7552595 0.0
RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION-REACTOME_MSIGDB_C2 97 -1.7552052 0.0
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S-REACTOME_MSIGDB_C230 -1.7525665 0.0021881838
RNA_POL_I_TRANSCRIPTION-REACTOME_MSIGDB_C2 65 -1.7518642 0.0023640662
IL2_SIGNALING_EVENTS_MEDIATED_BY_STAT5-NCI_NATURE_V4_PID 30 -1.7243161 0.0021929825
DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_THE_CENTROMERE-REACTOME_MSIGDB_C2 49 -1.723781 0.0025252525
VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS-KEGG_MSIGDB_C2 11 -1.723331 0.006185567
CTCF_PATHWAY-BIOCARTA_MSIGDB_C2 23 -1.7161859 0.0044345898
INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION-REACTOME_MSIGDB_C2 55 -1.7034966 0.0
SIGNALING_BY_FGFR_MUTANTS-REACTOME_MSIGDB_C2 42 -1.7021691 0.002232143
INFLUENZA_LIFE_CYCLE-REACTOME_MSIGDB_C2 88 -1.6870109 0.0
COREGULATION_OF_ANDROGEN_RECEPTOR_ACTIVITY-NCI_NATURE_V4_PID 58 -1.6786209 0.0
METABOLISM_OF_RNA-REACTOME_MSIGDB_C2 195 -1.6751395 0.0
TCGA_pathways_M0_M1
Page 1
d. TCGA pathways M0 M1
NAME SIZE NES NOM p-val FDR q-val
GENERIC_TRANSCRIPTION_PATHWAY-REACTOME_MSIGDB_C2 326 -2.1041558 0.0 5.302227E-4
OLFACTORY_SIGNALING_PATHWAY-REACTOME_MSIGDB_C2 29 -1.9542017 0.0 0.010386155
OLFACTORY_TRANSDUCTION-KEGG_MSIGDB_C2 46 -1.876282 0.0 0.03250705
MEIOTIC_RECOMBINATION-REACTOME_MSIGDB_C2 61 -1.865564 0.0 0.029584333
RNA_POL_I_PROMOTER_OPENING-REACTOME_MSIGDB_C2 41 -1.8378286 0.0 0.03859896
TASTE_TRANSDUCTION-KEGG_MSIGDB_C2 32 -1.7752548 0.004893964 0.09007122
PACKAGING_OF_TELOMERE_ENDS-REACTOME_MSIGDB_C2 35 -1.7562515 0.0016891892 0.10298665
RNA_POL_I_TRANSCRIPTION-REACTOME_MSIGDB_C2 66 -1.701523 0.0 0.19241117
SIGNALING_BY_FGFR_MUTANTS-REACTOME_MSIGDB_C2 32 -1.6666236 0.008130081 0.27214321
NEUROTRANSMITTERS_PATHWAY-BIOCARTA_MSIGDB_C2 5 -1.6100485 0.007155635 0.46722698
TIGHT_JUNCTION_INTERACTIONS-REACTOME_MSIGDB_C2 18 -1.609526 0.006756757 0.42711195
GLYCINE_SERINE_AND_THREONINE_METABOLISM-KEGG_MSIGDB_C2 27 -1.6079297 0.0099502485 0.39866075
TELOMERE_MAINTENANCE-REACTOME_MSIGDB_C2 62 -1.5963529 0.0016129032 0.41507018
DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_THE_CENTROMERE-REACTOME_MSIGDB_C2 50 -1.5660856 0.016949153 0.5240333
AMI_PATHWAY-BIOCARTA_MSIGDB_C2 13 -1.5652649 0.015280136 0.49310243
ION_TRANSPORT_BY_P_TYPE_ATPASES-REACTOME_MSIGDB_C2 27 -1.5518452 0.02173913 0.5278831
MEIOSIS-REACTOME_MSIGDB_C2 86 -1.5492297 0.0031595577 0.5106269
ION_CHANNEL_TRANSPORT-REACTOME_MSIGDB_C2 32 -1.5314323 0.025889968 0.5709465
SIGNALING_BY_FGFR1_MUTANTS-REACTOME_MSIGDB_C2 21 -1.5263451 0.047933884 0.5665365
BIOGENIC_AMINE_SYNTHESIS_HOMO_SAPIENS-WIKIPW 9 -1.522918 0.038655464 0.5545314
HISTONE_MODIFICATIONS_HOMO_SAPIENS-WIKIPW 50 -1.5044528 0.021909233 0.62121296
NICOTINE_ACTIVITY_ON_DOPAMINERGIC_NEURONS_HOMO_SAPIENS-WIKIPW 13 -1.494947 0.05141844 0.6435275
AMINE_DERIVED_HORMONES-REACTOME_MSIGDB_C2 6 -1.493296 0.02977233 0.6241212
RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION-REACTOME_MSIGDB_C2 99 -1.4880145 0.0075872536 0.6254596
FGFR_LIGAND_BINDING_AND_ACTIVATION-REACTOME_MSIGDB_C2 10 -1.4769261 0.04753521 0.66242075
MEIOTIC_SYNAPSIS-REACTOME_MSIGDB_C2 55 -1.4744071 0.018151816 0.64965343
PROXIMAL_TUBULE_BICARBONATE_RECLAMATION-KEGG_MSIGDB_C2 18 -1.4582627 0.04472272 0.7136957
RAPID_GLUCOCORTICOID_SIGNALING-NCI_NATURE_V4_PID 7 -1.4577448 0.06081081 0.69123477
INHIBITION_OF_INSULIN_SECRETION_BY_ADRENALINE_NORADRENALINE-REACTOME_MSIGDB_C2 21 -1.442105 0.06101695 0.7569545
SIGNALING_BY_FGFR1_FUSION_MUTANTS-REACTOME_MSIGDB_C2 18 -1.4355049 0.06514084 0.7702666
TRANS_SULFURATION_PATHWAY_HOMO_SAPIENS-WIKIPW 10 -1.4296039 0.085141905 0.78006935
HEDGEHOG_SIGNALING_PATHWAY_HOMO_SAPIENS-WIKIPW 13 -1.4256426 0.0822898 0.77888834
CELL_CELL_JUNCTION_ORGANIZATION-REACTOME_MSIGDB_C2 37 -1.4113475 0.041269843 0.8395694
GLUCURONIDATION-REACTOME_MSIGDB_C2 5 -1.4042214 0.05820106 0.8586595
AMYLOIDS-REACTOME_MSIGDB_C2 50 -1.4023662 0.04262295 0.84534746
GLOBO_SPHINGOLIPID_METABOLISM_HOMO_SAPIENS-WIKIPW 18 -1.4002512 0.073426574 0.8345487
MYOGENESIS-REACTOME_MSIGDB_C2 22 -1.3998605 0.07177814 0.81428343
Supplemental Table S7. List of mutations and associated drug sensitivities 
 
drug gene wilcox_pval t_test mean_wt_DSS mean_mut_DSS
1 Venetoclax Diagnosis vs. Refractory 0,00226 0,00897 29,2 12,8
2 Venetoclax FAB M1 vs. M5_diag. 0,00866 0,00851 37,3 25,1
3 Cytarabine RAS 0,01416 0,08591 9,6 24,1
4 Venetoclax Relapse vs. Refractory 0,01865 0,02447 26,1 12,8
5 Trametinib RAS 0,02620 0,09738 6,0 16,3
6 Trametinib Diagnosis vs. Relapse 0,03101 0,06435 4,2 11,8
7 Everolimus Frozen_Fresh 0,03606 0,09881 2,4 5,7
8 Trametinib FAB M1 vs. M5_diag. 0,03680 0,07187 8,9 1,9
9 Trametinib NPM1 0,03940 0,01243 9,6 3,1
10 Everolimus Diagnosis vs. Refractory 0,11444 0,22043 3,0 5,8
11 Sunitinib FAB M1 vs. M5_diag. 0,12121 0,19059 4,3 1,4
12 Idarubicin RAS 0,12282 0,10532 22,8 29,8
13 Idarubicin FAB M1 vs. M5_diag. 0,12554 0,16490 30,5 24,5
14 Everolimus FAB M1 vs. M5_diag. 0,13203 0,13618 6,3 0,5
15 Idarubicin Frozen_Fresh 0,13301 0,12420 22,0 26,3
16 Ruxolitinib NPM1 0,14537 0,02299 9,6 4,2
17 Trametinib Diagnosis vs. Refractory 0,16187 0,15477 4,2 10,8
18 Everolimus Relapse vs. Refractory 0,17871 0,32378 3,2 5,8
19 Venetoclax Frozen_Fresh 0,18082 0,10716 28,1 21,6
20 Idarubicin Diagnosis vs. Refractory 0,19172 0,28736 25,3 20,8
21 Venetoclax RAS 0,19777 0,27290 26,8 20,8
22 Idarubicin Diagnosis vs. Relapse 0,19909 0,15054 25,3 20,6
23 Sunitinib Complex 0,20222 0,32328 2,7 4,5
24 Ruxolitinib RAS 0,22438 0,31416 7,2 11,9
25 Venetoclax NPM1 0,26701 0,26567 24,5 29,0
26 Sunitinib FLT3 0,26981 0,21163 2,4 5,6
27 Everolimus RAS 0,27145 0,46084 3,1 5,0
28 Ruxolitinib Diagnosis vs. Relapse 0,28587 0,49977 6,5 8,5
29 Trametinib Complex 0,29516 0,27705 4,9 10,0
30 Ruxolitinib Diagnosis vs. Refractory 0,30088 0,31062 6,5 10,7
31 Venetoclax IDH 0,32818 0,28148 24,6 28,8
32 Trametinib IDH 0,33092 0,16948 8,7 4,8
33 Ruxolitinib FAB M1 vs. M5_diag. 0,35281 0,35408 10,5 4,8
34 Sunitinib NPM1 0,35483 0,31272 2,5 4,6
35 Sunitinib RAS 0,35519 0,00655 3,6 0,6
36 Ruxolitinib Complex 0,37353 0,68062 6,8 8,0
37 Cytarabine Complex 0,37478 0,08931 12,0 7,0
38 Cytarabine IDH 0,39743 0,13498 12,8 9,0
39 Trametinib Frozen_Fresh 0,39946 0,52127 6,4 8,3
40 Venetoclax Complex 0,41278 0,38479 26,1 18,8
41 Trametinib FLT3 0,41773 0,70657 7,1 8,4
42 Ruxolitinib Frozen_Fresh 0,45627 0,76764 7,4 8,2
43 Idarubicin NPM1 0,47450 0,55698 23,1 24,9
44 Cytarabine NPM1 0,47450 0,59499 12,1 10,3
45 Idarubicin Complex 0,48350 0,58502 23,4 20,8
46 Everolimus Complex 0,49618 0,58626 3,0 4,8
47 Everolimus Diagnosis vs. Relapse 0,49632 0,95280 3,0 3,2
48 Idarubicin IDH 0,50185 0,51823 24,4 22,3
49 Venetoclax FLT3 0,53232 0,55355 25,4 28,0
50 Cytarabine FAB M1 vs. M5_diag. 0,53680 0,69828 10,8 12,0
51 Sunitinib Relapse vs. Refractory 0,54002 0,19564 4,8 1,8
52 Ruxolitinib FLT3 0,55562 0,74704 7,6 8,6
53 Sunitinib Frozen_Fresh 0,58439 0,56017 3,1 4,1
54 Ruxolitinib Relapse vs. Refractory 0,62160 0,60323 8,5 10,7
55 Sunitinib Diagnosis vs. Relapse 0,63677 0,50101 3,3 4,8
56 Venetoclax Diagnosis vs. Relapse 0,64343 0,37570 29,2 26,1
57 Cytarabine FLT3 0,66599 0,27110 12,2 9,3
58 Cytarabine Frozen_Fresh 0,69956 0,32953 10,0 13,9
59 Ruxolitinib IDH 0,75332 0,41310 8,6 6,3
60 Idarubicin FLT3 0,77370 0,80359 23,5 24,3
61 Sunitinib IDH 0,78133 0,66622 3,4 2,7
62 Cytarabine Diagnosis vs. Relapse 0,79264 0,51644 11,7 9,9
63 Everolimus IDH 0,79897 0,61098 3,7 2,7
64 Everolimus NPM1 0,79897 0,69477 3,6 2,8
65 Everolimus FLT3 0,87788 0,93862 3,3 3,5
66 Cytarabine Diagnosis vs. Refractory 0,92148 0,95802 11,7 12,0
67 Cytarabine Relapse vs. Refractory 0,94328 0,71522 9,9 12,0
68 Idarubicin Relapse vs. Refractory 0,94328 0,96927 20,6 20,8
69 Sunitinib Diagnosis vs. Refractory 0,96094 0,33278 3,3 1,8
70 Trametinib Relapse vs. Refractory 0,97902 0,84063 11,8 10,8







Supplemental Figure S1. Drug plate layouts. (A) 96-well plate for FC assay and (B) 
384-well plate for CTG assay. To compare the DSS scores between FC and CTG-based 
assay, only the concentrations present in the FC layout were used. Drug concentrations 









1 2 3 4 5 6 7 8 9 10 11 12
A BzCl 0.1 KOMB1 KOMB2 KOMB3 KOMB4 KOMB5 KOMB6 KOMB7 KOMB8 KOMB9
B BzCl 1 10 1 0.1 10 0.25 0.1 KOMB10 KOMB11 KOMB12 KOMB13
C KOMB26 10 100 10 1 100 2.5 1 KOMB14 KOMB15 KOMB16 KOMB17
D DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO
E KOMB27 50 300 30 3 300 25 10 BzCl KOMB18 KOMB19 KOMB20
F KOMB28 100 1000 100 10 1000 75 100 KOMB21 KOMB22 KOMB23 BzCl
G KOMB29 1000 10000 1000 100 3000 250 1000 KOMB24 KOMB25 KOMB26 KOMB27
H DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO BzCl DMSO DMSO
Venetoclax Cytarabine Idarubicin Everolimus Ruxolitinib Trametinib Sunitinib
1 2 3 4 5 6 7 8 9 10 11 12
A
B DMSO 0.1 1 0.1 0.01 1 0.025 0.1 0.1 DMSO
C DMSO 0.3 3 0.3 0.03 3 0.75 0.3 0.3 DMSO
D DMSO 1 10 1 0.1 10 0.25 1 1 DMSO
E DMSO 3 30 3 0.3 30 0.75 3 3 DMSO
F DMSO 10 100 10 1 100 2.5 10 10 DMSO
G BzCl 50 300 30 3 300 7.5 30 30 BzCl
H BzCl 100 1000 100 10 1000 25 100 100 BzCl
I BzCl 300 30000 300 30 30000 75 300 300 BzCl
J BzCl 1000 100000 1000 100 100000 250 1000 1000 BzCl
K BzCl KOMB1 KOMB2 KOMB3 KOMB4 KOMB5 KOMB6 KOMB7 BzCl
L KOMB8 KOMB9 KOMB10 KOMB11 KOMB12 KOMB13 KOMB14
M KOMB15 KOMB16 KOMB17 BzCl KOMB18 KOMB19 KOMB20
N KOMB21 KOMB22 KOMB23 BzCl KOMB24 KOMB25 KOMB26 KOMB27
O
P
Venetoclax Cytarabine Idarubicin Everolimus Ruxolitinib Trametinib Sunitinib Quizartinib
 Supplemental Figure S2. Ex vivo cell culturing causes changes in cell 
compositions. Representative scatter plots (SSC vs. CD45+) of two AML samples 
measured by FC at day 0 and day 3. The granulopoietic cell population (represented by 
the SSChigh/CD45dim gates) was diminished and/or side scatter decreased in several 
samples as shown with the 6862 sample. Differentiation of monoblasts/promonocytes 
towards more mature monocytes based on the increment of SSCmid/CD45high and 
CD14+ cell populations was observed in many M5 cases as illustrated with the 6525 
sample. Ex vivo culturing resulted in two clear separate cell populations in the SSC/CD45 





















































 Supplemental Figure S3. Drug sensitivity comparison between CTG and FC-based 
assay on individual drugs. The comparison was made between drug sensitvity scores 
calculated from CTG-based bone marrow mononuclear cell and FC-based CD45+ 
leukocyte viability. Each dot represents one patient and the line connects the two readouts 
from the same patient. Venetoclax shows higher DSS scores (lower IC50) when 
measured with flow cytometry whereas trametinib, sunitinib and ruxolitinib shows higher 
DSS scores (lower IC50) when measured with CTG. CTG measures the ATP levels and 
thus the metabolic activity of the cells, whereas FC measure the number of live cells 














































 Supplemental Figure S4. IC50 values for distinct cell populations in AML and 2-3 
healthy control samples. Blue dots represent AML samples (n=33) and orange dots 





























































































































































































































































Figure S5. Venetoclax effect on CD34+CD38- LSCs vs. bulk CD34+CD38+ blasts. (A) 
A FC scatter plot representation of venetoclax effect on CD34+CD38- vs. bulk CD34+38+ 
blasts of patient sample 6688_2. The red highlighted value is the percentage of live cells 
relative to DMSO control treated wells at day 3. (B) Comparison for nine AML samples, 
which had distinct CD34+CD38- and CD34+CD38+ populations. The line connects the 
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 Supplemental Figure S6. BCL2 family expression for each FAB class analyzed 
from Hemap and TCGA data sets. Heatmap representation of gene expression levels 
in different AML subtypes or healthy cells derived from the (A) Hemap data set or the 










































































































































 Supplemental Figure S7. BCL2, MCL1, BCL2L1 expression for each AML FAB class 
and control samples. Expression of BCL2 (A), MCL1 (B) and BCL2L1 (C) in different 
















































































































































































































































































































































































































Supplemental Figure S8. Synergistic activity of different rational drug combinations 
in AML. Heatmap of the calculated BLISS synergy scores for the indicated drug 
combinations. The number after the short drug names represents the drug concentration 
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 Supplemental Figure S9. Synergy between MEK inhibitor trametinib and JAK1/2 
inhibitor ruxolitinib with Bcl-2 inhibitor venetoclax in AML. Dose–response matrices 
of delta synergy scores achieved at indicated doses of venetoclax combined with 
trametinib (top panels) or ruxolitinib (lower panels) in four patient samples. The black 
boxes represent the highest synergy score areas. The BLISS synergy method was used 
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